CD206⁺ IL-4R ⁺ MACROPHAGES ARE DRIVERS OF ADVERSE CARDIAC REMODELING IN ISCHEMIC CARDIOMYOPATHY

Qiongxin Wang, PhD;^{1,2,3} Mohamed Ameen Ismahil, PhD;^{1,3} Yujie Zhu, MD, PhD;^{1,3} Gregg Rokosh, PhD;^{1,3} Tariq Hamid, PhD;^{1,3} Guihua Zhou, MD, PhD;¹ Steven M. Pogwizd, MD;¹ Sumanth D. Prabhu, MD^{1,3}

¹Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL ²Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China, ³Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO

Running title: Alternatively activated macrophages promote adverse cardiac remodeling

Corresponding Author:

Sumanth D. Prabhu, MD Lewin Distinguished Professor and Chief Division of Cardiology Washington University School of Medicine 660 S. Euclid Ave CB 8086 St. Louis, MO 63110 Tel: 314-362-8908 Fax: 314-454-5550 Email: prabhu@wustl.edu

NONSTANDARD ABBREVIATIONS AND ACRONYMS

1 **ABSTRACT**

BACKGROUND: Cardiac CD206⁺ macrophages expand acutely after myocardial infarction (MI) to promote wound healing; however, their role in chronic heart failure (HF) is unknown. We 4 tested the hypothesis that cardiac CD206⁺ macrophages expressing interleukin(IL)-4R α are key drivers of adverse left ventricular (LV) remodeling in HF.

6 **METHODS AND RESULTS:** Adult male C57BL/6 mice underwent non-reperfused MI to induce 7 HF, or sham operation, and cardiac macrophages were profiled using flow cytometry. As 8 compared to sham, CD206⁺ macrophages steadily expanded in post-MI hearts during LV 9 remodeling, such that at 8 w post-MI they comprised ~85% of all macrophages. These 10 macrophages were robustly proliferative and predominantly C-C motif chemokine receptor (CCR2)⁻ and major histocompatibility complex (MHC)II^{hi}, with >90% of CD206⁺CCR2⁻ 11 12 macrophages expressing the resident macrophage marker LYVE-1. CD206⁺ macrophage 13 abundance correlated with LV dysfunction and fibrosis. Nearly half of CD206⁺ macrophages 14 expressed IL-4R α , and the majority of CD206⁺IL-4R α^+ macrophages co-expressed the profibrotic protein found in inflammatory zone (FIZZ)1. IL-4-polarized bone marrow derived CD206⁺ 15 16 macrophages also exhibited marked upregulation of FIZZ1 and induced FIZZ1-dependent 17 myofibroblast differentiation of cardiac mesenchymal stem cells (cMSCs), in part related to DLL-18 4/Jagged1-Notch1 signaling. Intramyocardial adoptive transfer of M[IL-4], but not M[IL-10], CD206⁺ 19 macrophages to naïve mice, induced progressive LV remodeling over 4 weeks, 20 increasing fibrosis, cardiomyocyte hypertrophy, and apoptosis. Myeloid-specific IL-4R α gene 21 deletion in established HF (initiated 4 w post-MI) in IL-4R $\alpha^{t/f}$ LysM-Cre^{ERT2} mice significantly 22 reduced CD206⁺ macrophage proliferation and effectively depleted CD206⁺IL-4R α^+ cardiac 23 macrophages. This was associated with abrogation of LV remodeling progression, reduction of 24 cardiac fibrosis, and improved neovascularization. *In vivo* IL-4R α gene silencing in mice with 25 established HF effectively depleted cardiac $CD206^+$ IL-4R α^+ macrophages and reversed LV

 remodeling, improving fibrosis, neovascularization, and dysfunction, and suppressed both local 27 and systemic inflammation. Lastly, alternatively activated CD206⁺ and CD163⁺ macrophages were significantly expanded in human failing hearts and correlated with fibrosis. The majority of 29 CD163⁺ macrophages expressed IL-4R α and FIZZ3, the human homolog of FIZZ1. **CONCLUSION:** Cardiac CD206⁺IL-4R α ⁺ macrophages proliferate and expand in HF and are key mediators of pathological remodeling and fibrosis, in part through the secretion of FIZZ1. 32 Inhibition of CD206⁺ macrophage IL-4R α signaling alleviates LV remodeling in ischemic cardiomyopathy.

- 34
- 35 Key Words: CD206⁺ macrophages; fibrosis; heart failure; interleukin 4 receptor-α; inflammation

36 **CLINICAL PERSPECTIVE**

37

38 *What is new?*

- ³⁹ In the failing heart after myocardial infarction (MI), CD206⁺ macrophages, primarily CCR2⁻, 40 MHCII^{hi}, and LYVE1⁺, robustly proliferate with a subpopulation expressing IL-4R α ; myeloid-specific IL-4R α deletion or IL-4R α silencing *in vivo* tempered CD206⁺ 41 42 macrophage proliferation and alleviated LV dysfunction, fibrosis, and remodeling.
- 43 M[IL-4] CD206⁺ bone-marrow derived macrophages induced upregulation of *Fizz1*, and 44 FIZZ1-dependent cardiac mesenchymal myofibroblast differentiation; intramyocardial 45 adoptive transfer of M[IL-4] macrophages induced cardiac remodeling and fibrosis.
- 46 Humans exhibit expansion of alternatively activated macrophages in the failing heart 47 marked by CD206 and CD163 expression, with predominance of a subpopulation 48 expressing IL-4R α and Fizz3, the human homolog of *Fizz1*.

49 *What are the clinical implications?*

- 50 An expanded pool of alternatively activated CD206⁺IL-4R α^* cardiac macrophages are key 51 drivers of LV remodeling in heart failure, inducing an immuno-fibrotic and para-52 inflammatory response in part dependent on FIZZ1.
- 53 Targeting IL-4 signaling in CD206⁺ macrophages represents a potential therapeutic 54 approach to limit long-term cardiac remodeling in heart failure.

55 **INTRODUCTION**

56 Heart failure (HF) is characterized by local and systemic inflammation.¹ In ischemic 57 cardiomyopathy, activated macrophages expand in the failing myocardium and contribute to 58 tissue injury and adverse left ventricular (LV) remodeling.¹⁻⁵ Cardiac macrophages may be 59 classified as C-C motif chemokine receptor (CCR2)⁻ resident macrophages that are embryonically derived and maintained independent of blood monocytes, and CCR2⁺ 60 61 macrophages that are derived from monocyte recruitment.⁶⁻⁸ Acutely after myocardial infarction 62 (MI), resident CCR2⁻ macrophages are lost and replaced by Ly6C^{hi}CCR2⁺ monocytes and 63 inflammatory CCR2⁺ macrophages that later transition to reparative macrophages to facilitate 64 wound healing, accompanied by attendant proliferation of surviving resident macrophage 65 populations.^{3,6,9-11} Notably, in chronic ischemic cardiomyopathy, well after MI healing, the 66 expanded cardiac macrophage pool stems from both locally proliferating resident macrophages 67 and recruited CCR2⁺ monocytes,^{2,3,5,6,12} with overall predominance of locally sourced (CCR2⁻) 68 cells.^{3,5,12} CCR2⁺ macrophage abundance correlates with adverse LV remodeling in human 69 $\text{HF},^2$ whereas inhibiting CCR2⁺ monocyte infiltration sub-acutely after MI improves LV 70 remodeling in mice,⁵ identifying CCR2 as a potential therapeutic target. In contrast, the roles of 71 locally sourced macrophage populations in the pathogenesis of LV remodeling in established 72 HF are poorly defined.

73 Resident cardiac macrophages express several marker genes including *Timd4, Lyve1,* 74 and classical alternatively-activated (M2-like) macrophage markers *Cd163* and *Mrc1*.^{2,6,13,14} In the naïve mouse heart, CD206 (*Mrc1*)-expressing resident macrophages are primarily CCR2– 75 and express high levels of the markers *Ym1* and *Fizz1*. ¹⁵ After acute MI, CD206⁺ 76 macrophages 77 expand in the infarct and border zone (peaking at 7 d post-MI)^{15,16} to promote wound healing 78 and limit adverse remodeling.^{15,17} CD206⁺ macrophages are activated by Th2 cytokines IL-4/13, 79 and IL-10.¹⁸⁻²⁰ IL-4/13 are important inducers of a reparative and pro-fibrotic phenotype,^{18,19,21} 80 signaling through Type I or II IL-4 receptors containing the common alpha chain IL4R α , resulting

81 in STAT6-mediated activation of *Arg1*, *Mrc1*, *Fizz1* (*Retnla*), *Ym1*, and secretion of C-C motif 82 chemokine ligands (CCL)-17 and -22.^{18,20,22,23} In vivo administration of IL-4 acutely after MI 83 improves wound healing and remodeling via the modulation of CD206⁺ macrophages. However, 84 this beneficial effect is lost when IL-4 is given late after MI.^{15,24}

85 These prior studies highlight CD206⁺ macrophages as key mediators of the post-MI 86 wound healing response. However, the importance of this macrophage population in the 87 chronically failing heart, which exhibits a considerably different immune cell profile,^{1,11} is 88 unknown. In chronic ischemic cardiomyopathy, locally sourced and proliferating cardiac 89 macrophages exhibit much greater *Mrc1* and *Fizz1* expression than monocyte-derived 90 macrophages.⁵ Moreover, in chronic pulmonary and renal disease, persistent M[IL-4/13] 91 activation or M2-like macrophage recruitment can contribute to tissue fibrosis, $21,25$ whereas we 92 have previously shown that the post-MI failing heart exhibits increased IL-4/13 expression 93 coincident with a Th2 $CD4^+$ T-cell profile.²⁶ Hence, here we tested the hypothesis that 94 expansion of cardiac CD206⁺ macrophages, activated by IL-4 receptor signaling, are key 95 mediators of LV remodeling in chronic ischemic HF.

96 **METHODS**

97 **Mouse models***.* All mouse studies complied with the National Research Council's Guide 98 for the Care and Use of Laboratory Animals (revised 2011) and were locally approved by 99 Institutional Animal Care and Use Committees at the University of Alabama at Birmingham and 100 Washington University in St. Louis. CD45.2 (#000664) and CD45.1 (#002014) C57BL/6 mice, 101 Fizz1^{-/-} mice (#029976), and LysM-Cre^{ERT2} mice (#031674) were purchased from Jackson 102 Laboratory. Floxed IL4R α (IL4R $\alpha^{t/f}$) mice²⁷ were originally obtained from Dr. Frank Brombacher 103 (University of Cape Town) and bred with LysM-Cre^{ERT2} mice to generate IL-4R $\alpha^{t/f}$ LysM-Cre^{ERT2} 104 mice that allow for tamoxifen-inducible myeloid-specific deletion of IL-4R α . To induce Cre-105 mediated recombination, mice were fed tamoxifen citrate chow (40 mg/kg/d; Inotiv TD.130860).

106 As 400mg/kg tamoxifen citrate is sufficient to induce recombination,²⁸ IL-4R $\alpha^{f/f}$ LysM-Cre^{ERT2} mice were considered to reach stable myeloid-specific IL4Rα deletion after 2 w of feeding. Male mice were used for experiments unless otherwise indicated. Mice were housed in temperature- controlled cages under a 12-hour light-dark cycle and given free access to water and regular chow. A total of 248 male and 37 female mice at 8-10 weeks of age were used. After terminal experiments, mice were euthanized by isoflurane inhalation (2%).

 Murine surgical procedures. Permanent coronary ligation to induce large MI and ischemic HF, and control sham surgery, were performed under general anesthesia with 1-1.5% 114 inhaled isoflurane and mechanical ventilation as previously described.^{4,26,29-31} For macrophage 115 adoptive transfer, cell suspensions (1x10⁶ polarized macrophages in 50 μ L sterile PBS) or sterile PBS control alone were injected intramyocardially into the free wall of left ventricle (10 **LA**/site x 5 sites) in naïve C57BL/6 male recipient mice.

 Echocardiography*.* M-mode and 2-dimensional echocardiography were performed 119 under 2% inhaled isoflurane anesthesia (with 98% O₂) and continuous ECG monitoring using a VisualSonics Vevo 3100 High-Resolution System and 30 MHz MX400 transducer with a heated, 121 bench-mounted adjustable rail system.^{4,26,29,32,33} Imaging was performed in the parasternal long- axis and short-axis views. LV chamber volume in end-diastole (EDV) and end-systole (ESV) were quantitated using the area-length method from long-axis images captured in ECG-gated Kilohertz Visualization mode. Systolic function was indexed by LV ejection fraction (EF), calculated as [(EDV−ESV)/EDV] * 100. Stroke volume was defined as EDV−ESV. LV mass (mg) 126 was calculated as 1.05^* [(IVSWTd+EDD+PWTd)³-(EDD)³], where IVSWTd and PWTd are interventricular septal and LV posterior wall thickness at end-diastole, and EDD is the LV end-diastolic diameter derived from M-mode tracings.

 Gene expression analysis. Total RNA from LV remote zones (≈10 mg), macrophages and cMSCs was extracted using Trizol (Invitrogen, 15596026) and Qiagen RNAeasy Columns

131 (QIAGEN, ³⁴ and reverse transcribed to cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 43-688-14). cDNAs were subjected to qPCR using SYBR Green Master Mix (Applied Biosystems, A25742) and run on a ViiA 7 RT PCR System (Applied 134 Biosystems).^{32,35-37} Forward and reverse primer sequences are listed in *Supplemental Table 1*.

 Multiplex Luminex assay. Peripheral blood was coagulated on ice and centrifuged to separate serum. Cytokine Luminex assay of serum samples was performed in 96-well Bio-Plex Pro Mouse Cytokine microplates and analyzed using the Luminex reader (BIO-RAD, Bio-138 PlexTM 200 system) according to the manufacturer's protocol.³⁴ Bio-Plex Pro Mouse Cytokine 23-plex Assay (M60009RDPD), MIP-2 Set (171G6006M), TGF-β1 Set (171V4001M), Standards Group I (171I50001), Group II Standards (171I60001), TGF-β Standard (171X40001) and Reagent Kit V (12002798) were all purchased from BIO-RAD.

 Immunoblot analysis. Immunoblotting was conducted using standard protocols as 143 described previously,^{33,34,36} using antibodies against mouse Notch1 (Cell Signaling, 4380), NICD 144 (Cell Signaling, 4147) and α -SMA (Abcam, ab7817). GAPDH (Cell Signaling, 97166) and α -tubulin (Santa Cruz, 5286) were used as loading controls.

 Immune cell isolation and flow cytometry. Live mononuclear cells were isolated from peripheral blood and heart tissue and processed for flow cytometry as previously 148 described.^{26,29,38} After 1% paraformaldehyde fixation, isolated cells were resuspended in MACS buffer (PBS with 2 mM EDTA and 0.5% BSA) and preincubated for 10 min at 4°C with anti-150 mouse CD16/CD32 antibody (eBioscience, #14-0161-82) to block Fc γ receptors.³² Cells were then stained for surface membrane markers upon incubation with fluorophore-labeled anti-152 mouse CD45, F4/80, MERTK, CD11b, Ly6G, Ly6C, CD3, CD4, CD8, IL-4R α , IL-10R α , MHCII, LYVE1, and CCR2, and, for human cardiac mononuclear cells, anti-human CD45, CD64, CD206 and CCR2 for 1 h. Mouse cardiac mononuclear cells were then permeabilized with 0.5% Tween-20 for 20 minutes, followed by staining with anti-mouse CD206 and Ki67 for 1 h. All

 staining was performed on ice to maintain cell morphology. Flow cytometry was performed using a FACSdiva LSR-II flow cytometer (BD) and analyzed using FlowJo software v10.8.0. Specific details regarding the fluorophore-conjugated antibodies used are listed in *Supplemental Table 2*.

 (Immuno)histological analysis. Formalin-fixed, paraffin-embedded heart tissues were 161 sectioned at 5 um thickness, deparaffinized, and rehydrated. Cardiomyocyte cell membranes and capillaries were stained using Alexa Fluor (AF)555-conjugated wheat-germ agglutinin (Invitrogen, #W32464) and AF488-conjugated isolectin-IB4 (Invitrogen, #121411), 164 respectively.^{4,26,29,32}. After antigen retrieval, LV sections were stained with anti-mouse CD206 (1:50, R&D AF2535, secondary anti-goat AF555), Ki67 (1:50, eBioscience 14-5698-82, secondary anti-rat AF488), CD45.2 (1:50, eBioscience 14-0454-82, secondary anti-mouse 167 AF647), α -actinin (1:100, Sigma A2172, secondary anti-mouse AF555), IL-4R α (1:50, Invitrogen PA5-103142, secondary anti-rabbit AFF647) and FIZZ1 (1:50, R&D MAB-1523, secondary anti- rat AF488) or anti-human CD163 (1:100, Leica Biosystems CD163-L-CE, secondary anti-mouse 170 IgG1 AF647), IL-4R α (1:50, R&D MAB230, secondary anti-mouse IgG2a AF488) and FIZZ3 (1:50, R&D AF1359, secondary anti-goat AF555) antibodies. After permeabilization with 20 μ g/ml proteinase K, α -actinin stained LV sections were incubated with TUNEL reaction mix (Biotium 30063) for 2h at 37°C. CD206 or CD163 stained LV sections were incubated with 15 174 µM heat-dissociated collagen hybridizing peptide 5-FAM Conjugate (F-CHP) (3Hekix FLU300) 175 overnight at 4° C. In addition, LV frozen sections (8 μ m) were fixed with acetone/chloroform, rehydrated, and stained with anti-mouse F4/80 (1:100, Abcam ab6640, secondary anti-rat 177 AF488) and α -actinin (1:100, Sigma A2172, secondary anti-mouse AF555) antibodies. Nuclei were stained with DAPI. Images were acquired using a Nikon A1 confocal microscope. Fibrosis was measured in LV sections using Masson's Trichrome staining, and images were captured by a Nikon 80i Nomarski DIC microscope. Collagen (blue) staining percent of total cross-sectional

181 area was determined as previously described.^{4,26,29,32} Staining was quantified from more than 5 high-power fields (40x) per section using Nikon NIS-Elements software, version 4.60.00.

 Bone marrow macrophage culture and adoptive cell transfer. C57BL/6 (CD45.2) or 184 Fizz1^{-/-} mouse bone marrow (BM) cells were harvested aseptically and cultured in RPMI 1640 medium, supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (PS) and 30 ng/mL recombinant mouse macrophage-colony-stimulating factor (M-CSF, R&D, 416-ML) at 37°C. The supernatant was replaced with fresh complete medium containing 30 ng/mL M-CSF 188 every 3 days for the attached cells, following the protocol of Trouplin et al.³⁹ After 7 days of differentiation, BM-derived macrophages (BMDMs) were cultured in RPMI 1640 with 10% FBS and 1% PS for 24 h for M0 (resting) macrophages, with 40 ng/mL recombinant mouse IL-4 (R&D, 404-ML) for M[IL-4] macrophages, and with 40 ng/mL recombinant mouse IL-10 (R&D, 417-ML) for M[IL-10] macrophages. Polarized macrophages were then mechanically detached, and cell aliquots were stained with anti-mouse CD45, F4/80 and CD206 (*Supplemental Table 2*) and analyzed using a flow cytometer to evaluate macrophage purity. After 24 h of polarization, M0, M[IL-4] and M[IL-10] cells were rinsed with PBS and cultured in FBS-free medium for 3 h. The macrophage conditioned medium was subsequently collected for treatment of cardiac mesenchymal stem cells and fibroblasts, as described below. The polarized macrophages were used for studies of intramyocardial adoptive cell transfer into naïve male CD45.1 C57BL/6 mice as described above.

 In vivo **antisense oligonucleotide administration.** Second-generation chimeric 20- base IL-4R α antisense oligonucleotides (ASOs) (CCGCTGTTCTCAGGTGACAT) and control mismatched oligonucleotides (MM oligos) (CCGCTCATCACTGCTGACAT) were synthesized by Integrated DNA Technologies (IDT). All 20-base oligonucleotides were designed to avoid murine immune-stimulatory motifs, and contained phosphorothioate backbones and 2'-O-205 methoxyethylribose (MOE)-modification on bases 1–5 and 16–20 as described previously.^{40,41} Oligonucleotides were suspended in sterile saline and administered every 3 days (40 mg/kg,

207 total volume 10 μL saline/g body weight) by intraperitoneal injection.⁴¹ Male C57BL/6 sham- operated and HF mice (4 w post-MI) with comparable degrees of LV remodeling were 209 randomized to receive either IL-4R α ASOs (Ref 219428745, IDT) or MM oligos (Ref 219428746, IDT) for 4 w.

 In vivo **phagocytosis assay.** To assess cardiac macrophage phagocytosis *in vivo*, pHrodo™ green-E. coli bioparticles (Invitrogen, P35366) were injected intraperitoneally to mice (200 μg/mouse) 4 h before sacrifice. After sacrifice, heart mononuclear cells were collected and cell surface marker staining performed with anti-mouse CD45, F4/80, MERTK and CD206 as described above. Bioparticle uptake in live macrophages was measured by flow cytometry.

Cardiac mesenchymal stem cell (cMSC) studies *in vitro***.** Sca1⁺CD90⁺CD31–DDR2– cMSCs were isolated from mouse hearts and maintained in supplemented [DMEM]/Ham's F-12 218 culture medium as previously described, and used within 3-5 cell passages for all experiments. For isolated cell stimulation studies, cMSCs were treated at the indicated times with serum-free conditioned RPMI 1640 medium from M0, M[IL-4], or M[IL-10] macrophages described above 221 (or control media alone), with some experiments performed in the presence of either 1.5 $\mu q/mL$ Fizz1 neutralization antibody or IgG isotype control (antibodies-online.com, ABIN636644 and ABIN1881001, respectively). In separate studies, cMSCs were treated with recombinant mouse Fizz1 (Leinco Technologies, R1140) at the indicated concentrations and times in serum-free RPMI 1640 medium.

Collagen gel-contraction assays. These were performed as previously described.³³ Briefly, cMSCs in ice-cold 10% FBS DMEM medium mixed with 1 mg/mL rat tail collagen I were 228 plated in 48-well tissue culture plates at a density of $3x10^5$ cells/well. The cell suspension was incubated at 37°C for 30 minutes until gelation. After gel formation, an additional 0.5 mL of 10% 230 FBS DMEM medium was added to each well and incubated overnight at 37°C in a 5% CO₂ incubator. The supernatant was then removed and the gels treated with 0.5 mL conditioned

 RPMI 1640 medium from M0, M[IL-4], or M[IL-10] macrophages with 10% FBS (or media alone 233 control), with or without anti-Fizz1 or IgG isotype control (1.5 μ g/mL), as described above. Some experiments were performed upon incubation with IL-4 or IL-10 alone (40 ng/mL) in 10% FBS RPMI 1640 medium. The cells were cultured and treated for 5 d with medium change every 2 d. On day 5, the gels were detached from the wells using a pipette tip and incubated overnight. On day 6, the gels were imaged with a digital camera and gel area was measured using Image J software (1.51j8, NIH).

 siRNA transfection of cMSCs. cMSCs were transfected with siRNA using INTERFERin Reagent (Polyplus, 101000028) according to the manufacturer's protocol. Control siRNA (4390843) and siRNA targeting Notch1 (4390771) were purchased from Invitrogen.

 Cardiac fibroblast studies *in vitro***.** Mouse cardiac fibroblasts were purchased from iXCells biotechnologies (10MU-015) and grown in fibroblast growth medium (MD-0011) at 37°C in a humidified 5% CO2 atmosphere. Cells were used within 1-3 passages and treated with M0, M[IL-4], or M[IL-10] conditioned medium for 24 h.

 Human studies. Following patient consent, failing heart tissue was procured from patients with advanced (NYHA IV) HF with reduced EF undergoing LV assist device (LVAD) placement at the University of Alabama at Birmingham (UAB) under the auspices of Institutional Review Board (IRB) approved protocol #X090810003. Non-failing control heart tissues were obtained from donor hearts technically unsuitable for heart transplantation from the Alabama Organ Center. All protocols using human heart samples were approved by the UAB IRB. Failing and control human heart tissues were used for cardiac immune cell isolation and subsequent flow cytometry, as well for histological analysis. Clinical characteristics of human HF subjects and donor controls are shown in *Supplemental Table 3.*

 Statistical Analysis. All group data are mean ± SD. All statistical analyses were performed with GraphPad Prism 9 (GraphPad Software). Normality was assessed using the Shapiro-Wilk test, whereas group variances were compared using the Brown-Forsythe test. For

 normally distributed data, a two-tailed unpaired Student's *t* test with equal or unequal variance was used for two-group analyses, and 1- or 2-way ANOVA with Tukey's post-test was used for multi-group analyses. Additionally, 2-way repeated-measures ANOVA with Dunnett's multiple comparison test was used to analyze time series pre-post data. For non-normal distributions, the Mann-Whitney U test was used for 2-group analyses. Pearson R correlation test was used for linear dependence analyses. Specific approaches are in the figure legends. A *p* value of <0.05 was considered statistically significant.

RESULTS

266 **Cardiac CD206⁺ macrophages progressively expand during the development of chronic HF post-MI.** Cardiac macrophage subsets were profiled using flow cytometry at various timepoints following non-reperfused large MI during the development of ischemic HF, 4,26,29,36 and in sham-operated controls (*Figure 1A*). As shown in *Figures 1B-C and S1A*, 270 following MI there was significant cardiac accumulation of both overall CD45⁺ leukocytes and 271 total F4/80⁺MERTK⁺ macrophages in a biphasic manner, with high levels at 48 h after injury, subsequent decline by 2 w, followed by a second phase of re-expansion up to 8 w post-MI during chronic LV remodeling and failure. In the failing heart 8 w post-MI, macrophages comprised nearly two-thirds (~63%, or ~140,000 cells per heart) of all cardiac leukocytes and were increased by ~9-fold over macrophage levels in sham-operated hearts. Similar dynamics 276 were observed for the blood levels of pro-inflammatory Ly6C^{high} monocytes, an important source 277 of infiltrating macrophages, $3,5,10,32,42$ during the progression of ischemic HF. No significant 278 differences were observed in the levels of patrolling $Ly6C^{low}$ monocytes between sham-operated and HF mice at any time point evaluated (*Figures S2A-C*).

 We next further evaluated macrophage subsets in the mouse heart. Naïve murine hearts harbored low numbers of macrophages (~20,000/heart), of which ~90% expressed the resident macrophage marker CD206 (*Figure 1C*). However, acutely (48 h) after MI, CD206⁺ macrophages comprised only ~20% of overall macrophages in the heart, in the setting of a

284 marked expansion of CD206⁻ macrophages early after MI. Thereafter, both the frequency and 285 absolute number of CD206⁺ macrophages steadily increased in post-MI hearts during the progression of LV remodeling, such that at 8 w post-MI ~85% of cardiac macrophages 287 expressed CD206. In contrast, CD206⁻ macrophage levels decreased markedly by 2 w post-MI, and then exhibited smaller sustained increases in chronically failing hearts thereafter. Both populations were significantly increased as compared to sham-operated hearts at all timepoints post-MI. Hence, macrophages expand significantly in the chronically remodeled and failing heart post-MI, and most of these macrophages express CD206.

Cardiac CD206⁺ macrophages robustly express IL-4Rα in chronic HF. Two key 293 activators of CD206⁺ macrophages are IL-4/13, acting via Type I or II IL-4 receptors (IL-4R) 294 containing the common subunit IL4R α ,⁴³⁻⁴⁵ and IL-10, signaling through the IL-10 receptor (IL-295 10R) complex upon binding to the high affinity IL-10R α (IL-R1) subunit.^{46,47} As illustrated in 296 *Figure 1D*, both CD206⁺IL4R α^+ and CD206⁺IL-10R α^+ macrophage subpopulations were 297 significantly increased in comparison to sham-operated hearts at all time points after MI. 298 However, there was substantial expansion of the CD206⁺IL4R α^* population over time, such that 299 at 8 w post-MI, levels of CD206⁺IL-4R α^* cells (~45,000 per heart) were ~8-fold higher than 300 CD206⁺IL-10R α^* cells and comprised ~42% of all CD206⁺ macrophages in the chronically failing 301 heart. In contrast, at 1 w post-MI, during the healing phase, $CD206$ ⁺IL-10R α ⁺ macrophages 302 were more abundant than $CD206$ ⁺IL-4R α ⁺ cells, comprising ~40% of all $CD206$ ⁺ macrophages 303 in the heart. Notably, neither IL-4R α nor IL-10R α were abundantly expressed by cardiac 304 CD206⁻ macrophages (<3% of cells) at any timepoint post-MI, and CD206⁻ macrophages 305 expressing either IL-4R α or IL-10R α numbered fewer than 500 cells/heart in the chronic stages 306 of LV remodeling (*Figure S1B*). In addition, IL-4R α and IL-10R α expression was also very low in 307 blood neutrophils (<1.5%), Ly6C^{low} monocytes (<2%) and Ly6C^{high} monocytes (<5%) in both 308 sham and HF mice (*Figure S2*).

 Regarding Th2 cytokines, serum levels of IL4 and IL-10 were significantly higher in MI mice as compared with sham mice during both the healing phase (1 w) and chronic remodeling phase (8 w) post-MI, whereas levels of IL-13 and TGF-β1 were comparable in sham and MI mice at all timepoints (*Figure S3A*). In contrast, serum levels of the pro-inflammatory cytokines 313 TNF- α , IFN-γ, IL-1β, MCP-1 and MIP-2 α in HF mice were increased over sham controls during both the early and late phases of remodeling after MI (*Figure S3B*), consistent with ongoing 315 systemic inflammation in HF mice. Hence, CD206⁺ macrophages in the failing heart primarily 316 express IL-4R α (versus IL-10R α); this is accompanied by increased circulating levels of both IL-4 and IL-10.

318 **CD206⁺ macrophages in the failing heart proliferate, are primarily CCR2⁻, MHCII^{hi}, and LYVE1⁺** 319 **and correlate with LV dysfunction and fibrosis.** At 8 w post-MI, HF mice exhibited significant LV systolic dysfunction and fibrosis (*Figure 2A and S4A*). Cardiac CD206⁺ 320 321 macrophage abundance inversely correlated with LVEF ($r = 0.695$), and directly correlated with 322 border and remote zone fibrosis (r = 0.755 and 0.644, respectively). Tissue co-staining with anti-323 CD206 and fluorescein-conjugated collagen hybridizing peptide (CHP) that recognizes 324 denatured collagen⁴⁸ revealed that CD206⁺ macrophages were primarily found in areas of 325 collagen turnover in the failing heart, with >98% of macrophages associated with CHP-positive 326 regions in the infarct and border zones, and >80% CHP-associated cells in the remote 327 myocardium (*Figure 2B*). To infer the source of CD206⁺ macrophage expansion in the failing 328 heart, we measured the expression of markers CCR2, MHCII, and LYVE1 by flow cytometry 329 (*Figure 2C*). In sham hearts, >90% CD206⁺ macrophages were CCR2⁻, and of these, ~95% 330 were LYVE-1⁺, indicating a primarily resident macrophage population. In failing hearts, the 331 proportion of CD206⁺CCR2⁻LYVE1⁺ macrophages decreased significantly but remained high at 332 ~80% of total CD206⁺ cells, suggesting resident cell predominance but with an increased

333 contribution from monocyte-derived macrophages. Moreover, in both sham and failing hearts, 334 the majority (\approx 70%) of CD206⁺ macrophages were MHCII^{hi}.

335 Resident macrophage expansion requires local cell proliferation. As shown in *Figure 2D* 336 *and S4B*, immunostaining for CD206 and the cell proliferation marker Ki67 revealed that both 337 total CD206⁺ and Ki67⁺CD206⁺ macrophages were robustly expanded in the failing heart (8 w 338 post-MI) as compared to sham. Cell density was greatest in the infarct zone (855 cells/mm²; 9% 339 Ki67⁺), followed by the border zone (584 cells/mm²; ~8% Ki67⁺) and then the remote zone (290 340 cells/mm², Ki67 positivity ~3% similar to sham hearts). Complementary assessment using flow 341 cytometry demonstrated that in both sham and failing hearts only CD206⁺ macrophages 342 exhibited Ki67 positivity (*Figure 2E*). Moreover, as compared to sham, failing hearts evidenced 343 \sim 3-fold higher levels of CD206⁺Ki67⁺ macrophages (\sim 10% total), confirming augmented local 344 proliferation of CD206⁺ macrophages. In parallel, myocardial gene expression of Th2 cytokines 345 IL-4 and IL-10 (but not IL-13) and classical alternatively-activated macrophage markers *Mrc1* 346 *(CD206), Arg1, Ym1* and *Fizz1* was significantly increased in failing versus sham hearts (*Figure* 347 *S4C*), Concomitantly, the expression of fibrotic genes $(Col)1\alpha1$, Col1 $\alpha2$, and Col3 $\alpha1$ was 348 markedly increased in failing hearts. Collectively, these data support expansion of a Th2/M2-like 349 immuno-fibrotic response in the chronically failing heart post-MI.

IL-4 polarization *in vitro* **induces a profibrotic phenotype in CD206⁺** 350 **macrophages.** 351 Bone marrow-derived macrophages (BMDMs) were polarized with either IL-4 or IL-10 352 (40ng/mL), or medium alone (M0 control), for 24 h (*Figure 3A*). Flow cytometry indicated that 353 while BMDMs were primarily CD206⁺ under resting (M0) conditions, both IL-4 and II-10 354 exposure augmented BMDM CD206 expression to ~98-99% of total cells. As shown in *Figure* 355 3B, the expression of signature M2 genes^{15,18,20,49,50} Mrc1, Arg1, and *Ym1* significantly increased 356 in both M[IL-4] and M[IL-10] macrophages (with much more *Arg1* and *Ym1* expression in M[IL-4] 357 cells) as compared to non-polarized M0 macrophages. In contrast, expression of *Fizz1* (found in 358 inflammatory zone 1), a protein secreted during Th2 responses^{51,52} and implicated in

359 myofibroblast differentiation and lung fibrosis,^{53,54} only increased in M[IL-4] macrophages, and to extraordinary levels (>7,500-fold). Conversely, *B7-H4* was exclusively, albeit modestly, upregulated in M[IL-10] macrophages. Changes in macrophage gene expression were noted after 4 h of polarization (*Figure S5A*) and were maintained or augmented after 48 h (*Figure S5B*). A range of responses was observed for inflammatory and repair-associated genes in BMDMs after 24 h of polarization *in vitro* (*Figure S6A*). Surprisingly, there was no upregulation of profibrotic genes TGF-β1 and platelet-derived growth factor (PDGF)-BB in M[IL-4] and M[IL10] macrophages as compared to M0 cells, although there was augmented expression of tissue inhibitor of matrix metalloproteinase (TIMP)-1 and TIMP-3 in both M[IL-4] and M[IL-10] macrophages.

 In parallel experiments, conditioned medium was collected from M0, M[IL-4] and M[IL-10] 370 macrophages and applied to Sca1⁺CD90⁺CD31⁻DDR2⁻ cardiac MSCs³³ (*Figure 3A*). cMSC gene expression was then evaluated after 6 and 16 h of exposure. Short-term (6 h) exposure to M[IL-4] medium induced significant upregulation of the proliferation genes *PCNA*, *Mki67, CyclinB1* and *CyclinD1* as compared to M0-medium, and to a greater extent than upon exposure to M[IL-10] medium. Longer-term (16 h) exposure induced similar expression 375 responses for cMSC pro-fibrotic genes, including α -smooth muscle actin *(* α *-SMA*), *Col1* α *1*, *Col12*, and *Col31* (*Figure 3C*). The functional impact of macrophage polarization on cMSCs 377 was assessed using collagen gel contraction assays³³ after 5 d of exposure to M0, M[IL-4], M[IL-10] medium, or medium alone control. As illustrated in *Figure 3D*, M[IL-4] medium exposure induced robust gel contraction, significantly greater than with exposure to either M0 or M[IL-10] medium (or control), consistent with vigorous cMSC myofibroblast differentiation. Importantly, exposure to complete medium containing IL-4 or IL-10 alone (40 ng/mL) did not induce cMSC gel contraction (*Figure S6B*), indicating an indispensable role for CD206⁺ macrophages in IL-4-induced cMSC myofibroblast differentiation. Similarly, 24 h treatment with

384 M[1L-4] medium robustly increased α -SMA protein expression in mouse cardiac fibroblasts as compared with similar treatment with M0 or M[IL-10] medium (*Figure S6C*). Collectively, these data suggest that IL-4-mediated macrophage polarization supports pro-fibrotic responses in concert with striking upregulation of *Fizz1*.

 Adoptive transfer of M[IL-4] macrophages to naïve hearts induces cardiac dysfunction and fibrosis. To evaluate the in vivo cardiac effects of M[IL-4] and M[IL-10] 390 macrophages, we adoptively transferred 1x10⁶ M0, M[IL-4], or M[IL-10] bone marrow-derived macrophages from CD45.2 male mice to naïve WT CD45.1 male mice (PBS control) via intramyocardial injection, with subsequent follow-up over 4 w (*Figure 4A*). Immunostaining of injection sites of recipient hearts 30 minutes post-injection confirmed successful transfer of M0, M[IL-4], and M[IL-10] donor macrophages (*Figure S7A*). Serial echocardiography of recipient mice revealed progressive and significant LV chamber dilatation, with increased EDV and ESV, and systolic dysfunction, with reduced LVEF, along with LV hypertrophy, evidenced by increased LV mass, IVSWTd, and PWTd by echocardiography and increased normalized heart weight, in M[IL-4] macrophage recipients, but not in PBS, or M0 or M[IL-10] macrophage recipients (*Figures 4B and S7B and D*). Stroke volume was comparable over time in all four groups (*Figure S7C*). Histological analysis showed significantly increased patchy interstitial fibrosis in M[IL-4]-recipient hearts as compared with PBS, M0, and M[IL-10] recipient hearts (*Figure 4C*), along with augmented cardiomyocyte cross-sectional area and apoptosis (*Figures 4D and S7E*). Importantly, CD45.2 and CD206 co-staining of recipient hearts demonstrated donor macrophage persistence in adoptive transfer recipients, but to a significantly greater level in M[IL-4] recipient mice. M[IL-4] (but not M0 or M[IL-10]) macrophage transfer also induced 406 expansion of native resident CD206⁺ macrophages. Both CD45.2⁺ donor and CD45.2⁻ recipient 407 CD206⁺ macrophages expansion occurred primarily at sites of collagen turnover and fibrosis in recipient hearts, with stronger such association for donor macrophages (*Figures 4E and S7F*),

409 There was no evidence of pro-inflammatory Ly6C^{hi} monocytosis in any recipient mouse group 410 (*Figure S7G*), suggesting the absence of systemic inflammation after transfer. Collectively, 411 these data establish that M[IL-4] polarized macrophages are sufficient to induce chronic cardiac 412 remodeling, hypertrophy, and fibrosis, and a microenvironment supporting CD206⁺ macrophage 413 expansion.

Myeloid-specific IL-4Rα deletion in HF suppresses cardiac CD206⁺ 414 **macrophage** 415 expansion and improves LV remodeling. Among myeloid cells, IL-4R α expressions occurred 416 primarily in macrophages, with low levels in monocytes and neutrophils (*Figure S2*), and among 417 macrophages, primarily in CD206⁺ macrophages (Figures 1D and S1B). Hence, to establish the 418 bole of CD206⁺IL4R α^* macrophages in HF, we used IL-4R α^{ff} LysM-Cre^{ERT2} mice. Given the 419 importance of the IL-4 axis in wound healing after acute $MI^{15,24}$ and our observations that 420 cardiac CD206⁺IL-4R α^* macrophage expansion in ischemic HF occurs most prominently \geq 4 w 421 post-MI, we induced myeloid IL-4R α deletion during late remodeling. Male and female IL-4R $\alpha^{t/f}$ 422 and IL-4R $\alpha^{t/t}$ LysM-Cre^{ERT2} HF mice with comparable LV remodeling at 4 w post-MI (or sham-423 operated controls) were randomized to receive tamoxifen diet for 6 weeks (*Figure 5A*). In male 424 mice, echocardiography revealed significant LV dilation and systolic dysfunction in both HF 425 groups 4 w post-MI as compared to sham (*Figure 5B*). In contrast, as compared with tamoxifen-426 fed IL-4R $\alpha^{t/f}$ HF mice, tamoxifen treatment for 6 w in IL-4R $\alpha^{t/f}$ LysM-Cre^{ERT2} HF mice resulted in 427 lower LVEDV and ESV, better LVEF and stroke volume (SV), and smaller heart size and 428 normalized heart and lung weight (*Figures 5B, S8A-B*). Moreover, histological analysis revealed 429 less border and remote zone fibrosis, smaller cardiomyocyte area, and improved capillary 430 density in male IL-4R $\alpha^{t/f}$ LysM-Cre^{ERT2} HF mice versus IL-4R $\alpha^{t/f}$ HF mice (*Figures 5C, S8C*). Myeloid IL-4R α deletion in HF in male mice also decreased levels of total leukocytes, CD206⁺ 431 and CD206⁻ (and CD206⁻IL4R $\alpha^{\text{+}}$) macrophages, CD206⁺IL4R $\alpha^{\text{+}}$ and CD206⁺IL10R $\alpha^{\text{+}}$ 432 433 macrophages, and proliferating Ki67⁺CD206⁺ macrophages in the heart, as well as Ly6C^{hi} and

434 Ly6C^{hi}IL-4R α^* monocytes (but not Ly6C^{low} monocytes) in the blood, as compared to HF mice 435 without myeloid IL-4R α deletion (*Figures 5D-F, S8D-F*). There were no effects of myeloid IL-436 $4R\alpha$ deletion on any parameter in sham male mice.

437 Comparable tamoxifen-induced effects were observed in female IL-4R $\alpha^{t/f}$ LysM-Cre ERT2 438 versus IL-4R $\alpha^{t/f}$ HF mice with regard to improvements in LV remodeling and systolic function 439 (albeit with less pronounced differences in LVEDV) (*Figure S9A-B*), heart and lung gravimetry 440 and weight (*Figure S9C-D*), and reductions in cardiac leukocytes and total macrophages (Figure 441 S10A), CD206⁺ and CD206⁻ macrophages, CD206⁺IL4R α^+ and CD206⁺IL10R α^+ macrophages, 442 and CD206⁻IL4R α^* macrophages (*Figures S10B-C*). As in males no effects of myeloid IL-4R α 443 deletion on any of these parameters were observed in sham-operated female mice. Collectively, 444 these results indicate that CD206⁺IL4R α^* macrophages are a key expanded myeloid cell 445 population in the failing heart that is necessary for driving progressive inflammation and 446 pathological cardiac remodeling, fibrosis, and dysfunction. Moreover, IL-4R α expression marks 447 a macrophage subpopulation with high proliferative capacity in the failing heart.

448 **IL-4R silencing** *in vivo* **reverses LV remodeling, reduces cardiac fibrosis, and** 449 **improves neovascularization in HF.** To explore whether the macrophage IL-4R α axis could 450 be exploited for therapeutic benefit in HF, we selectively silenced IL-4R α expression *in vivo* 451 using optimized antisense oligonucleotides (ASOs) targeting IL-4R α mRNA. 40,41 IL-4R α 452 signaling mainly occurs in hematopoietic and lymphoid cells.⁴⁵ In humans, there is very low IL-453 4R RNA expression in heart cardiomyocytes and fibroblasts, with much more pronounced 454 expression in immune cells, and in endothelial and smooth muscle cells 455 (https://www.proteinatlas.org/ENSG00000077238-IL4R/single+cell+type/heart+muscle). To 456 assure targeting of cardiac macrophages with this systemic approach, we performed flow 457 cytometry to evaluate IL-4R α expression in cardiac leukocytes. As shown in *Figure S11*, in both 458 sham and failing hearts, ~92% of all IL-4 $R\alpha^+$ CD45⁺ leukocytes were macrophages

459 (F4/80⁺MERTK⁺), while ~98% of IL-4R α^* macrophages in failing hearts were CD206⁺. Moreover, 460 circulating monocytes and neutrophils exhibited low levels of IL-4R α expression (*Figure S2*). 461 Hence, IL-4R α ASOs represent a feasible and directed approach for dual inhibition of IL-4 and 462 lL-13 signaling 45 in cardiac CD206 $^+$ IL-4R α^{+} macrophages.

 Male sham-operated and HF mice with comparable degrees of LV remodeling at 4 w post-464 MI were randomized to receive either IL-4R α ASOs or MM oligos (40 mg/kg every 3 days) for 4 weeks (*Figure 6A*). Body weight was comparable between the two sham groups and two HF groups over the 4 w treatment period (*Figure S12A*). Serial echocardiography revealed significant and expected LV dilation and systolic dysfunction in both HF groups as compared to sham groups (*Figures 6B and S12B*). Sham-operated mice exhibited no changes in LVEDV, 469 LVESV, stroke volume (SV), and LVEF during treatment with either IL-4R α ASOs or MM oligos. HF mice treated with MM oligos evidence progressive increases in LV chamber size, and 471 reductions in LVEF and SV, over 4 w. In contrast, $HF\text{-}IL\text{-}4R\alpha$ ASO mice, which exhibited LV remodeling similar to HF-MM oligo mice at 4 w post-MI, exhibited significant reductions in EDV and ESV, and improvements in SV and EF, indicative of reverse remodeling. Lung and heart gravimetric analysis at 8 w post MI revealed substantially attenuated pulmonary edema and 475 cardiac hypertrophy in HF-IL-4R α ASO HF mice versus HF-MM oligo mice, without impact on spleen weight (*Figures 6C and S12C*).

477 Histological evaluation with trichrome staining indicated significantly increased border and 478 remote zone interstitial fibrosis in MM oligo-treated failing hearts as compared to MM oligo-479 treated sham hearts (*Figure 6D*). Impressively, IL-4Rα ASO treatment profoundly decreased 480 both border and remote zone fibrosis in failing hearts. Fibrotic area in IL-4R α ASO-treated sham 481 hearts was comparable to that of MM oligo-treated sham hearts. Isolectin B4 and wheat-germ 482 agglutinin staining (*Figure 6E*) indicated that both HF-MM oligo mice and HF-IL-4R α ASO mice 483 exhibited significantly increased myocyte cross-sectional area and lower myocardial

484 capillary:myocyte ratio versus their respective sham groups. Importantly, however, myocyte 485 area was lower and capillary: myocyte ratio was higher in HF -IL-4R α ASO mice versus HF-MM 486 oligo mice, indicating alleviation of pathological hypertrophy and capillary rarefaction.

IL-4R silencing in HF depletes cardiac CD206⁺ IL-4R + 487 **macrophages and** 488 **suppresses their proliferative and phagocytic capacity.** As shown in *Figures S13A and 6F*, 489 4 w of IL-4R α ASO treatment significantly reduced the number of total CD45⁺ leukocytes (by $~145\%$), total F4/80⁺MERTK⁺ macrophages (by $~53\%$), and both CD206⁺ and CD206⁻ 490 491 macrophages (by ~50%) in the failing heart. Moreover, IL-4R α ASO treatment specifically and 492 profoundly depleted CD206⁺IL-4R α^* cardiac macrophages, while mildly augmenting CD206⁺IL-493 10R α^* macrophages in the failing heart (*Figure 6F*). IL-4R α ASO administration did not impact 494 leukocyte and total macrophage abundance in sham hearts. Notably, IL-4R α ASO therapy did 495 not impact in circulating IL-4 levels (nor IL-13 and TGF-β1 levels) in HF mice, whereas serum IL-10 was significantly decreased (*Figures 6G and S13B*). Remarkably, total CD206 496 497 macrophages, including CD206⁻IL-4R α^* and CD206⁻IL-10R α^* macrophages, in failing hearts 498 were also diminished by IL-4R α ASO treatment (*Figure S13A*). Additionally, IL-4R α ASO 499 treatment impacted CD206⁺ macrophage function in failing hearts, significantly reducing (by 500 ~50%) both CD206⁺ macrophage cell proliferation (Ki67 staining) and phagocytic capacity 501 (assessed in vivo using fluorescent bioparticles) in HF-IL-4R α ASO mice as compared with HF-502 MM oligo mice (*Figures 6H-I*). The latter data are consistent with IL-4 serving as a potent 503 stimulator of macrophage proliferation.^{15,55}

 504 IL-4R α ASO treatment in HF mice also abrogated systemic inflammation as evidenced 505 by normalization of circulating Ly6C^{hi} monocytosis (and levels of Ly6C^{hi}IL-4R α^* monocytes) and 506 serum levels of pro-inflammatory protein mediators TNF- α , MCP-1, MIP-2α and IL-1β toward 507 those observed in sham mice (*Figure S13C-D*). Serum IFN-γ levels, however, were not 508 impacted by IL-4R α ASO treatment and remained high in HF-IL-4R α ASO mice as compared to

509 sham. Importantly, IL-4R α ASO treatment in HF mice also alleviated T-cell expansion in both the circulation and failing heart, with significant reductions in peripheral blood and cardiac CD4⁺ 510 511 and CD8⁺ T cells in in HF-IL-4R α ASO mice as compared with HF-MM oligo mice (*Figure S14*). 512 Additionally, IL-4R α expression was very low (~1-2%) in blood and heart CD4⁺ and CD8⁺ T cells 513 in both sham and HF mice treated with MM oligo or IL-4R α ASOs. Taken together, these data 514 indicate that in vivo IL-4R α mRNA silencing was highly effective in improving pathological 515 cardiac remodeling, hypertrophy, fibrosis, and dysfunction, and in suppressing local and 516 systemic inflammation in chronic ischemic HF.

Fizz1 is essential for CD206⁺517 **macrophage-induced myofibroblast activation.** FIZZ1, 518 also known as resistin-like molecule α (*Retnla*), is a 9.4 kDa cysteine-rich secreted protein 519 produced mostly by macrophages during Th2 responses.⁵⁰⁻⁵² As described above, macrophage Fizz1 expression exponentially increased exclusively after M[IL-4] polarization (>7,500-fold after 24 h and >100,000-fold after 48 h) polarization and not with M[IL-10] polarization (*Figures 3B and S5B*), and coincided with M[IL-4] macrophage-induced myofibroblast differentiation of cMSCs (*Figure 3C*). Accordingly, we further evaluated the role of Fizz1 in pro-fibrotic cellular responses. Exposure of cultured cMSCs to recombinant mouse (rm) Fizz1 induced, in a dose- dependent manner, the expression of proliferative genes *PCNA, Mki67, CyclinB1* and *CyclinD1* 526 early (2 h), and profibrotic genes α -SMA, Col1 α 1, Col1 α 2, and Col3 α 1 late (16 h), after treatment (*Figure S15*), analogous to changes observed with M[IL-4] medium treatment (*Figure 3C*). To determine the need for FIZZ1 in M[IL-4]-induced cMSC responses, we used anti-Fizz1 antibody to neutralize endogenous Fizz1 in M[IL-4] conditioned medium. As shown in *Figure S16*, compared to IgG control, anti-Fizz1 significantly reduced the expression of mitotic genes, α -SMA (by 40%) and *Col3* α 1 in M[IL-4] conditioned media-treated cMSCs. Furthermore, anti-Fizz1 abrogated collagen gel contraction induced by M[IL-4] conditioned media (*Figure 7A*), a

533 phenomenon recapitulated by the use of Fizz1^{-/-} BMDMs (*Figure 7B)*, indicating that secreted 534 Fizz1 is essential for M[IL-4]-induced cMSC myofibroblast differentiation and activation.

535 Notch signaling is critical for cell proliferation, differentiation, and development, and 536 homeostasis;⁵⁶ Notch ligand binding to Notch receptors leads to release of Notch intracellular 537 domain (NICD) and subsequent transcription of target genes, including α -SMA, Cyclin D1, 538 Cyclin A and NF- κ B.⁵⁶ As α -SMA expression is critical for myofibroblast fate of mesenchymal 539 stromal cells,^{33,57}, we assessed the importance of Notch signaling in Fizz1-mediated α -SMA 540 expression in cMSCs. Fizz1 exposure significantly upregulated cMSC gene expression of the 541 Notch1 ligands DLL-4 and Jagged1 within 30 minutes (*Figure 7C*), followed by increased protein 542 expression of Notch1, NICD and α-SMA within 24 h (*Figure 7D*). Importantly, Notch1 siRNA 543 knockdown prevented α -SMA (and NICD) upregulation in Fizz1-treated cMSCs, suggesting a 544 critical role for DLL-4/Jagged-Notch1 signaling in the pro-fibrotic effects of M[IL-4] macrophage-545 secreted FIZZ1.

546 In view of the importance of FIZZ1 in M[IL-4]-induced myofibroblast differentiation, we 547 next examined Fizz1 expression and spatial distribution using immunostaining in failing hearts 548 from MM oligo- and IL-4R α ASO-treated mice (8 w post-MI). Consistent with flow data, a robust 549 (~11-fold) expansion of CD206⁺ macrophages (both IL-4R α^+ and IL-4R α^-) was observed in MM 550 oligo-treated failing hearts versus sham hearts, especially in the border zone (*Figure 7E*). IL-551 4R α staining was observed near exclusively in CD206⁺ cells (*Figure S17*), further supporting 552 CD206⁺ macrophage-specificity of IL-4R α silencing, and Fizz1⁺ staining was near exclusively 553 spatially localized to IL-4R α^* cells (~98% Fizz1⁺) in all groups (*Figure S17*). IL-4R α^* Fizz1⁺ cells 554 comprised ~50% cardiac CD206⁺ macrophages in HF-MM oligo mice (*Figure 7E*). IL-4Rα ASO 555 treatment significantly decreased IL-4R α ⁺Fizz1⁺ (and IL-4R α ⁻Fizz1⁻) CD206⁺ macrophages in 556 failing hearts, and also diminished IL-4R α expression (assessed by fluorescence intensity) (*Figure 7E*). (*Figures 7E and Figure S17*). Hence, IL-4R α silencing in HF reduced CD206⁺ 557

 macrophage FIZZ1 expression in the failing heart concomitantly with improvements in cardiac fibrosis. Taken together with the *in vitro* studies above, our results suggest that *Fizz1* may be a 560 key contributor to the tissue level pro-fibrotic effects of CD206⁺IL-4R α^* macrophages in the failing heart.

IL-4Rα⁺Fizz3⁺ 562 **alternatively activated macrophages expand and directly correlate** 563 **with fibrosis in human failing hearts.** To understand translational relevance, we lastly 564 explored whether alternatively activated resident macrophages are expanded in human HF. As 565 mentioned above, resident cardiac macrophages express classical M2-like markers *Mrc1* 566 (CD206) and CD163.^{2,6,13,14} Cardiac mononuclear cells were isolated from the LV apex procured 567 from advanced HF patients during LVAD implantation, and from control donor hearts unsuitable 568 for transplantation. Analogous to murine HF, flow cytometry indicated significant expansion 569 (~10-fold) of CD206⁺ macrophages (CD45⁺Autofluorescence⁺CD64⁺) in human failing hearts 570 versus control, with ~20% of CD206⁺ macrophages expressing CCR2 (*Figure 8A*). Human 571 failing hearts also exhibited substantial (>200-fold) interstitial fibrosis versus control hearts, with 572 most (~95%) CD163⁺ macrophages found in association with areas of collagen turnover (*Figure* 573 *8B*), analogous to murine failing hearts. *Fizz3* (resistin, *Retn*), the human homolog of murine 574 *Fizz1,* is expressed by M[IL-4/13] human macrophages and resembles mouse FIZZ1 with 575 respect to sequence and function.^{58,59} Accordingly, we performed immunostaining for IL-4R α , 576 Fizz3 and CD163, a widely used marker for alternatively-activated human macrophages.⁶⁰ As shown in *Figure 8C*, human failing hearts exhibited significant expansion (~6-fold) of CD163⁺ 577 578 macrophages (both IL-4R α^+ and IL-4R α^-) as compared to control hearts. Fizz3⁺ staining was 579 near exclusively spatially localized to IL-4R α^* cells (~98% Fizz3⁺) in both human control and 580 failing hearts, similar to the IL-4R α and Fizz1 expression pattern observed in mouse hearts 581 (*Figure S17*). Importantly, IL-4Ra⁺Fizz3⁺ cells comprised the predominant CD163⁺ macrophage 582 subset in human failing hearts, with approximately two-thirds of CD163⁺ macrophages

583 expressing IL-4Rα and Fizz3⁺ (*Figure 8C*). CD163⁺ macrophage abundance directly correlated with cardiac fibrosis in human HF. Hence, analogous to murine HF, human failing hearts also evidence expansion of alternatively activated macrophages, likely with augmented IL-4 signaling and contributing to pro-fibrotic responses.

587 **DISCUSSION**

588 We describe a novel role for cardiac CD206⁺ macrophages alternatively activated by IL-589 4 receptor signaling in the progression of LV remodeling in ischemic cardiomyopathy. There are 590 several key findings. First, macrophages expressing CD206 comprised most macrophages in 591 the naïve heart. Following MI, cardiac CD206⁺ macrophages progressively expanded, especially 592 during the later stages of LV remodeling such that they comprised the predominant macrophage 593 population in chronic HF. Second, CD206⁺ macrophages were exclusively proliferative and 594 primarily CCR2⁻, MHCII^{hi}, and LYVE1⁺ suggesting a resident cell population, and correlated with 595 LV dysfunction and fibrosis. Second, a sizable subpopulation of these macrophages in HF 596 expressed IL-4R α ; this occurred with attendant increased systemic levels of IL-4. Third, M[IL-4] 597 (but not M[IL-10]) CD206⁺ BMDMs induced remarkable upregulation of *Fizz1*, and robust cMSC 598 myofibroblast differentiation. M[IL-4] CD206⁺ macrophage-induced myofibroblast differentiation 599 and activation were dependent on FIZZ1 secretion and mediated in part by FIZZ1 induction of 600 DLL-4/Jagged1-Notch1 signaling in cMSCs. Fourth, intramyocardial adoptive transfer of M[IL-4] 601 macrophages was sufficient to induce pathological cardiac remodeling and fibrosis. Fifth, 602 myeloid-specific IL-4R α deletion tempered cardiac CD206⁺ macrophage proliferation and 603 alleviated LV dysfunction, fibrosis, and adverse remodeling. Sixth, IL-4R α silencing *in vivo* was 604 highly effective in depleting CD206⁺IL-4R α^* macrophages, reducing FIZZ1 expression in the 605 failing heart, and reversing LV remodeling in mice with established HF. Lastly, humans exhibit 606 expansion of alternatively activated macrophages in the failing heart marked by CD206 and 607 CD163 expression, with predominance of a subpopulation expressing IL-4R α and Fizz3, the

608 human homolog of *Fizz1*. Collectively, these data establish that an expanded pool of 609 alternatively activated CD206⁺IL-4R α^* cardiac macrophages are key drivers of LV remodeling in 610 HF, inducing a Th2/M2-like immuno-fibrotic response in part dependent on FIZZ1. Targeting IL-611 4 signaling in CD206⁺ macrophages may represent a fruitful therapeutic approach to limit long-612 term cardiac remodeling in HF.

613 *Mrc1* (*Cd206*) and *Cd163* are typically expressed by resident cardiac macrophages 614 under steady state conditions.^{2,6,13,14} Moreover, in the naïve heart, CD206⁺ macrophages express high levels of classical M2-like genes such as *Ym1* and *Fizz1* and are primarily CCR2– 615 616 ¹⁵ suggesting a macrophage subset with minimal monocyte-dependence.⁶ Prior work has 617 shown that CD206⁺ macrophages expand during the first week after acute MI in the infarct and 618 border zone to promote infarct repair and functional restoration.¹⁵⁻¹⁷ Administration of IL-4 619 acutely (but not late) after MI also expands CD206⁺ macrophages in the infarcted heart and 620 recapitulates beneficial effects on post-MI cardiac healing.^{15,24} However, the role of this 621 macrophage population, and the impact of macrophage IL-4 signaling, in chronic LV remodeling 622 and ischemic HF has not been defined. The chronically failing heart is typically marked by 623 excessive tissue fibrosis.⁶¹ Notably, in chronic pulmonary,^{62,63} hepatic,⁴¹ and renal²⁵ disease 624 models marked by excessive fibrosis, alternatively activated (CD206⁺ or CD163⁺) macrophage 625 activation mediated by Th2 cytokines such as IL-4 contribute to disease progression. While we 626 have previously shown that the post-MI failing heart exhibits increased IL-4 expression and a 627 predominant Th2 CD4⁺ T-cell profile,²⁶ whether a similar pathophysiological axis contributes to 628 LV remodeling in ischemic cardiomyopathy is unknown.

629 **Cur studies show that CD206⁺ macrophages progressively expand after MI, with** 630 particularly robust levels during the later stages of LV remodeling. Beyond the initial infiltration of predominantly $(>80%)$ CD206⁻ macrophages into the heart early $(48 h)$ after MI, CD206⁺ 631 632 macrophages were the main subtype in the remodeling heart at 1 w post-MI and beyond,

633 comprising ~85% of all macrophages in HF. Moreover, in the failing heart 8 w post-MI, nearly 634 half of all cardiac $CD206⁺$ macrophages expressed IL-4R α . Notably, cardiac macrophage 635 proliferation was observed exclusively in CD206⁺ subpopulation in the failing heart. Although 636 spatially expanded throughout the myocardium, CD206⁺ macrophages were most abundant in 637 the infarct scar and border zone, and primarily in regions of collagen turnover and fibrosis. 638 Heightened macrophage proliferation was also mainly seen in the scar and border zones. This 639 suggests that progressive CD206⁺ macrophage expansion in these regions may contribute to 640 extracellular matrix remodeling, infarct expansion and LV chamber dilatation over time. Human 641 HF also evidenced marked expansion of alternatively activated (CD206⁺ or CD163⁺) cardiac 642 macrophages (consistent with a prior study of macrophages isolated from human failing hearts⁶⁴) 643 in association with regions of collagen denaturation and turnover, with a predominance of cells 644 expressing IL-4R α analogous to murine HF. In this regard, IL-4 is a known stimulator of tissue 645 macrophage proliferation and resident macrophage self-renewal^{55,65} that also augments 646 macrophage CD206 expression⁶⁶ and promotes M2-like cardiac macrophage differentiation.¹⁵ 647 Consistent with our prior studies, 26 IL-4 levels were increased both locally in the heart and 648 systemically, suggesting that heightened IL-4 signaling may contribute importantly to sustaining 649 local inflammation and macrophage expansion in failing myocardium.

650 **In both murine and human HF, the expanded cardiac CD206⁺ macrophage population** 651 vas primarily CCR2⁻ (~80%), MHCII^{hi}, and LYVE1⁺. In naïve¹⁵ and in sham-operated hearts, 652 CD206⁺ macrophages were also primarily CCR2⁻, albeit to much greater degrees (~95%) than 653 in failing hearts. As LYVE1 is considered a marker of resident macrophages, ⁶ this suggests a 654 predominantly resident macrophage population that is expanded in failing hearts, but also with a 655 dual (albeit lesser) contribution from CCR2⁺ monocyte-derived cells. Prior work has shown that 656 after MI the absence of CCR2 expression does not exclude a monocyte origin as recruited 657 macrophages over time may exhibit transcriptional identities nearly identical to resident

658 macrophages.⁶ Our study design did not incorporate macrophage lineage tracing to definitively 659 address this question. Nonetheless, our data are consistent with prior work indicating that 660 cardiac macrophages derive from both local macrophage proliferation and recruited monocytes 661 (locally-sourced cells comprising ~75%) in chronic ischemic HF.^{3,5} Given our observations that 662 the proportion of CCR2⁺ cells increased significantly in failing hearts, and that cardiac 663 macrophage abundance in post-MI HF was paralleled by similar dynamic changes in Ly6C^{high} 664 blood monocytes that source infiltrating macrophages, $3,5,6,10$ we propose that the expanded and 665 proliferative cardiac CD206⁺macrophage population derives from both resident and recruited 666 cells.

667 We evaluated the pathophysiological importance of CD206⁺IL-4R α^* expansion in the 668 failing heart by experimentally manipulating IL-4R α signaling, which occurs largely in immune 669 cells.⁴⁵ While both M[IL-4] and M[IL-10] macrophage polarization induced the upregulation of signature alternative macrophage activation genes, M[IL-4] polarization exclusively resulted in extraordinary upregulation of *Fizz1*, and functional myofibroblast differentiation of cMSCs, together with enhanced cMSC proliferative gene expression. Importantly, intramyocardial adoptive transfer of M[IL-4], but not M[IL-10], macrophages produced significant long-term LV chamber dilatation, dysfunction, and fibrosis in naïve recipients. Hence, IL-4-mediated activation of macrophages was sufficient to recapitulate chronic cardiac remodeling.

676 To establish the necessity of CD206⁺IL-4R α^* macrophages in the pathogenesis of 677 chronic LV remodeling, we evaluated the effects of myeloid IL-4R α deletion during established 678 HF on subsequent LV remodeling. This manipulation primarily impacted macrophages in HF, 679 given the very low levels of IL-4R α in neutrophils and monocytes. Notably, loss of macrophage 680 IL-4 signaling via IL-4R α suppressed CD206⁺ macrophage proliferation, abrogated the 681 progression of LV remodeling, improved LV systolic function and fibrosis, while suppressing 682 both CD206⁺ and CD206⁻ macrophages in the heart as well as systemic Ly6C^{hi} monocytosis in

683 the blood. Beneficial effects of macrophage IL-4R α deletion were observed in both male and 684 female mice. Hence, CD206⁺IL4R α^* macrophages are indispensable for sustaining a chronic 685 para-inflammatory response in failing myocardium that drives progressive cardiac remodeling in 686 HF.

687 To explore a potential therapeutic avenue, we performed *in vivo* gene silencing of IL-688 AR α using ASOs, an approach that primarily targeted cardiac CD206⁺ macrophages given the 689 aforementioned low distribution of IL-4R α expression observed in other myeloid and lymphoid 690 cell populations in chronic HF. IL-4R α silencing in chronic ischemic HF very effectively depleted 691 cardiac CD206⁺IL-4R α^* macrophages and suppressed their proliferation and phagocytic 692 capacity, while inducing impressive reverse LV remodeling with improvements in cardiac fibrosis, 693 neovascularization, and function, and suppression of both local and systemic inflammation (*e.g*., 694 blood and cardiac $CD4^+$ and $CD8^+$ T cell levels). Taken together, our results underscore the 695 pathological effects of chronic macrophage IL-4R α activation in the failing heart and establish 696 CD206⁺IL-4Rα⁺ macrophages as key mediators of pathological remodeling of the failing heart. 697 Our data support biological or pharmacological blockade of the IL-4/IL-4R α pathway as a novel 698 immunomodulatory paradigm in HF. For instance, antagonistic antibodies against IL-4R α are 699 currently being developed for allergic disorders in humans, 67 and could potentially be 700 repurposed for HF.

CD206⁺ macrophage abundance in murine failing hearts (or CD163⁺ 701 macrophage abundance in human HF) correlated with the extent of cardiac fibrosis in chronic HF, and a 703 prominent feature of IL-4-mediated CD206⁺ macrophage activation *in vitro* and *in vivo* was the induction of pro-fibrotic responses. Our data suggest that the protein FIZZ1 secreted by M[IL-4] macrophages may play an important role in this crosstalk, given: 1) *in vitro* studies demonstrating incredibly robust macrophage *Fizz1* upregulation upon IL-4 stimulation, 2) FIZZ1 dependence of the induction of cMSC myofibroblast differentiation by M[IL-4] macrophages,

 potentially via DLL-4/Jagged1-Notch1 signaling, 3) exclusive expression of Fizz1 by cardiac 709 CD206⁺IL-4Rα⁺ macrophages in chronic HF, and 4) exclusive expression of FIZZ3 (resistin), 710 the human homolog of FIZZ1,⁵⁸ by CD163⁺IL-4R α ⁺ macrophages in human failing hearts. FIZZ1 711 is secreted during Th2-type immune responses in mice.^{52,68} and induces myofibroblast differentiation and fibrosis in the lung, $53,54$ whereas FIZZ3 induces LV fibrosis and dysfunction 713 vhen overexpressed in rat heart⁶⁹ and is a serum risk prediction biomarker in HF patients.⁷⁰ Our data are consistent with a key pro-fibrotic function for FIZZ1 in the failing heart, secreted by 715 alternatively-activated CD206⁺IL-4R α^* macrophages as part of an overall Th2/M2-like 716 inflammatory milieu in the failing heart.²⁶ The elucidation of the precise role of Fizz1/Fizz3, and the potential for therapeutic Fizz1/Fizz3 blockade in HF, will require further study.

 In summary, we have established a novel immunoinflammatory framework in the failing 719 heart with an expanded pool of alternatively activated CD206⁺IL-4R α^* macrophages as key drivers of LV remodeling. These alternatively-activated macrophages induce a para- inflammatory, immuno-fibrotic response, in part dependent on FIZZ1 expression, that promotes 722 cardiac fibrosis and dysfunction. Our findings identify IL-4 signaling in CD206⁺ macrophages, and potentially FIZZ1/FIZZ3 elaboration, as novel and appealing therapeutic targets for immunomodulation to limit long-term cardiac remodeling in ischemic cardiomyopathy and HF.

ACKNOWLEDGEMENTS AND FUNDING

 This work was supported by National Institutes of Health R01 HL157999 and HL147549 grants to SDP, and R01 HL137046 to TH.

COMPETING INTERESTS

There are no relevant author financial interests.

733 **FIGURE LEGENDS**

Figure 1. Cardiac CD206⁺ 734 **macrophages robustly expand and express IL-4Rα in** 735 **heart failure (HF).** *A*, Protocol for cardiac macrophage profiling by FACS in C57BL/6 mice at 736 the indicated time points after non-reperfused myocardial infarction (MI) or sham operation. *B* 737 and *C*, representative flow cytometry scatter plots (*B*) and group quantitation for cardiac 738 macrophages (F4/80⁺MerTK⁺), and CD206⁺ and CD206⁻ subpopulations (C) from sham and MI 739 mice at the indicated times post-operation. Quantitation from naïve mice also shown. *D*, Representative flow plots and group data for IL-4R α and IL-10R α expression in cardiac CD206⁺ 740 741 macrophages from the same mouse groups. Statistics: unpaired Student's t test; ***p*<0.01 vs 742 respective sham group in C-D; ${}^{ss}p<0.01$ vs Sham-CD206⁻ in C, ${}^{ss}p<0.01$ vs Sham-IL-10R $\alpha^{\text{+}}$ in 743 *D*. N=6-8 per group.

Figure 2. Cardiac CD206⁺ macrophages are proliferative, primarily MHCIIhi 744 **and** 745 LYVE1⁺, and correlate with LV dysfunction and fibrosis in heart failure (HF). A, 746 Representative long-axis 2-dimensional echocardiograms at end-diastole and heart trichrome 747 stains from HF mice 8 w after non-reperfused myocardial infarction (MI) and sham controls, 748 along with correlations between cardiac CD206⁺ macrophage number and LV ejection fraction 749 (LVEF), and border and remote zone (BZ and RZ) fibrosis in failing hearts. *B*, Representative 750 low and high magnification confocal images of failing heart (8 w post-MI) infarct, border, and 751 remote zones (immuno)stained for CD206 (red) and collagen hybridizing peptide (CHP) (green), 752 with quantitation of CHP-associated and -unassociated CD206⁺ macrophages. DAPI (blue) was 753 used to label nuclei. Scale bar 50 μ m. **C**, Flow plots and quantitation of CCR2 and LYVE1 754 expression in CD206⁺ macrophages and LYVE-1 expression in CD206⁺CCR2⁻ macrophages in 755 sham and HF hearts 8 w post-surgery, *D*, Low and high magnification confocal images of 756 CD206 (red) and Ki67 (green) immunostains of sham, and the infarct, border and remote zones 757 of failing hearts 8 w post-surgery, and quantitation of CD206⁺ macrophages and Ki67

758 expression frequency. Nuclei labeled by DAPI (blue); yellow arrows indicate CD206⁺Ki67⁺ cells. Scale bar 50 µm. E, Flow plots and quantitation of Ki67 expression in both CD206⁺ and CD206⁻ cardiac macrophages from the same groups. Statistics: Pearson R correlation test in *Aa*; unpaired Student's t test in *C*-*E*. N=4-13 per group as indicated.

 Figure 3. IL-4-polarized bone marrow derived macrophages (BMDMs) induce cardiac mesenchymal stem cell (cMSC) myofibroblast differentiation *in vitro***.** *A*, Protocol for BMDM polarization and cMSC treatment with macrophage conditioned medium, and representative flow plots of F4/80 and CD206 expression in polarized BMDMs. *B*, Expression of the indicated genes in M0, M[IL-4], and M[IL-10] macrophages 24 h after polarization. *C*, Expression of the indicated genes in cMSCs treated with M0, M[IL-4], and M[IL-10] conditioned media for the indicated times, and representative cMSC-imbued collagen gel contraction assays upon exposure to M0, M[IL-4], and M[IL-10] conditioned media, or media alone (Ctrl), and quantitation of gel areas. Statistics: 1-way ANOVA with post-hoc Tukey's multiple comparison test; * *p*<0.05, ** *p*<0.01 vs. M0. N=5-6/group.

 Figure 4. Adoptive transfer of M[IL-4] macrophages to naïve hearts induces cardiac dysfunction and fibrosis. *A*, Protocol for intramyocardial adoptive transfer of M0, M[IL-4], and M[IL-10] bone marrow derived macrophages (BMDMs) or PBS vehicle to naïve mice. *B*, M-mode echocardiograms of M0, M[IL-4], and M[IL-10] BMDM recipient mice 4 w post- transfer (PBS control), along with group data for LV end-systolic and end-diastolic volume (ESV and EDV), ejection fraction (EF) at indicated times post-transfer, and for echocardiographic LV mass normalized to tibia length (TL), and end-diastolic interventricular septal and posterior wall thickness (IVSWT and PWT) at 4 w post-transfer. *C*, Representative trichrome stains of recipient hearts at 4 w post-transfer and corresponding quantitation of cardiac fibrosis. *D*, *Top*, cardiac wheat-germ agglutinin (WGA, red) staining and quantitation of myocyte cross-sectional area; *Middle*, low and high magnification images of TUNEL (green) stained nuclei in cardiomyocytes (α -Actinin, Red) and quantitation of apoptotic myocyte nuclei; and *Bottom*, Low

 and high magnification confocal images of CD206 (red) and CD45.2 (gray) immunostains and 785 quantitation of CD206⁺CD45.2⁺ and CD206⁺CD45.2⁻ macrophages in recipient hearts, all at 4 w post-transfer. Green arrows indicate apoptotic myocyte nuclei, red arrows indicate 787 CD206⁺CD45.2⁻ cells, and white arrows indicate CD206⁺CD45.2⁺ cells. DAPI (blue) was used to label nuclei. *E*, Low and high magnification confocal images of CD206 (red) and CD45.2 (gray) immunostaining and CHP staining (green), and quantitation of CHP-associated and - 790 unassociated, CD45.2⁺ and CD45.2⁻ CD206⁺ macrophage ratios in M[IL-4] recipient hearts 4 w post-transfer. Nuclei were labeled by DAPI (blue). Red arrows indicate CHP-unassociated 792 CD206⁺CD45.2⁻ cells and white arrows indicate CHP-unassociated CD206⁺CD45.2⁺ cells. Statistics: repeated-measures 1-way ANOVA with post-hoc Dunnett's multiple comparison test for time series within groups in *B*, 1-way ANOVA with post-hoc Tukey's multiple comparison test between groups in *B-D*, and unpaired Student's t test in *E*; **p*<0.05, ***p*<0.01 M[IL-4] vs. PBS; # *p*<0.05, ##*p*<0.01 M[IL-4] vs. M0; \$ *p*<0.05, \$\$*p*<0.01 M[IL-4] vs. M[IL-10]; *p*<0.05, *p*<0.01 vs. Bsln. N=6-8 per group as indicated.

Figure 5. Myeloid-specific IL-4Rα deletion suppresses cardiac CD206⁺ macrophages and alleviates LV remodeling in heart failure (HF). *A*, Protocol for myeloid-800 specific IL-4Rα ablation in IL-4Rα^{t/f}LysM-Cre^{ERT2} sham and HF mice (IL-4Rα^{t/f} mouse control) with tamoxifen administration in diet from 4 to 10 w post-MI or sham surgery. *B*, Representative long-axis 2D echocardiograms at end-diastole from male sham and HF mice after 6 w of tamoxifen (10 w post-surgery), along with directional changes in LV end-diastolic and end- systolic volume (EDV and ESV) and LV ejection fraction (EF) over this time. *C*, Representative 805 but trichrome stains of hearts from IL-4R $\alpha^{t/f}$ and IL-4R $\alpha^{t/f}$ LysM-Cre $^{\textsf{ERT2}}$ sham and HF mice after 6 w of tamoxifen (10 w post-surgery) along with fibrosis quantitation in the border and remote zone 807 (BZ and RZ). **D** and **E**, Representative flow plots for cardiac macrophages (F4/80⁺MerTK⁺), $\;\;$ CD206⁺ macrophages, and IL-4R α and IL-10R α expressing CD206⁺ subpopulations in IL-4R $\alpha^{t\prime t}$

809 and IL-4R α^{ff} LysM-Cre^{ERT2} HF mice, along with quantitative group data from both sham and HF 810 male mice after 6 w of tamoxifen. *F*, Representative flow plots and quantitation of Ki67 811 expression in cardiac CD206⁺ and CD206⁻ macrophages from IL-4R α^tf and IL-4R α^tf LysM-812 Cre^{ERT2} HF mice given tamoxifen for 6 w. Statistics: 2-way ANOVA with post-hoc Tukey's 813 multiple comparisons between groups in *B-E*; unpaired Student's t test in in *F*. N=7-11 per 814 group.

Figure 6. *In vivo* **IL-4Rα silencing depletes cardiac CD206⁺** 815 **macrophages and reverses LV remodeling in heart failure (HF). A**, Protocol for treatment with IL-4R α antisense oligonucleotides (ASOs) or mismatched (MM) control oligonucleotides (oligo) in HF mice from 4 to 8 w after non-reperfused myocardial infarction (MI) (sham controls). *B*, Representative long- axis 2-dimensional echocardiograms at end-diastole from sham and HF mice treated with IL- $4R\alpha$ ASOs or MM Oligos for 4 w (8 w post-surgery timepoint). Also shown are group data for LV end-diastolic and end-systolic volume (EDV and ESV) and ejection fraction (EF) over the 822 treatment period. C , Gross images of hearts from IL-4R α ASO- and MM Oligo-treated sham and HF mice, and group data for lung and heart weight (LW and HW) normalized to tibia length (TL). **D**, Representative trichrome stains of IL-4R α ASO- and MM Oligo-treated sham and failing hearts, and fibrosis quantitation in the border and remote zone (BZ and RZ). *E*, Representative cardiac isolectin B4 (IB4, green) and WGA (red) staining and quantitation of myocyte cross-827 sectional area and capillary: myocyte ratio in the LV RZ from IL-4R α ASO- and MM Oligo-treated sham and HF mice. *F*, *Left*, quantitation of cardiac CD206⁺ 828 macrophages, and *Middle* and *Right*, 829 flow plots and quantitation of IL-4R α and IL-10R α expressing subpopulations, in sham and HF 830 mice treated with IL-4R α ASOs or MM Oligos for 4 w. **G**, Serum levels of IL-4 and IL-10 from the same groups. *H* and *I*, Representative flow cytometry histograms, dot plots, and quantitation of 832 cardiac Ki67⁺ (H) or bioparticle⁺ (I) CD206⁺ and CD206⁻ macrophages in IL-4R α ASO- and MM Oligo- treated HF mice. Statistics: repeated-measures 1-way ANOVA with post-hoc Dunnett's

 multiple comparison test for time series within groups in *B*; 2-way ANOVA with post-hoc Tukey's multiple comparisons between groups in *B-F, H, I*; unpaired Student's t test in *G*. ***p*<0.01 vs. 836 respective Sham-MM Oligo; $^{tt}p<0.01$ vs. HF-MM Oligo at the same week post-surgery; $^{A}p<0.05$, **b**_p<0.01 vs. respective 4 w timepoint. N=5-8 per group.

Figure 7. Fizz1 is essential for CD206⁺838 **macrophage-induced myofibroblast** 839 **differentiation of cardiac mesenchymal stem cells (cMSCs).** *A*, cMSC-imbued collagen gel 840 contraction assays upon exposure to M[IL-4] bone marrow-derived macrophage (BMDM) 841 conditioned media or media alone control (Ctrl) containing isotype IgG or anti-Fizz1 antibody 842 with corresponding quantitation of gel areas. *B*, cMSC gel contraction assays upon exposure to 843 wild-type (WT) and Fizz1^{-/-} M0 or M[IL-4] BMDM conditioned media, and quantitation of gel 844 areas. N=3-5 per group for *A-B*. *C*, cMSC DLL-4 and Jagged1 gene expression after 30 845 minutes of treatment with either vehicle (Ctrl) or recombinant mouse (rm) Fizz1 50 ng/ml and 846 100 ng/ml. *D*, Immunoblotting and group quantitation for Notch1, Notch intracellular domain 847 (NICD), and α -smooth muscle actin (α -SMA) protein expression in cMSCs treated with either 848 vehicle Ctrl or rmFizz1 for 24 h following scrambled or Notch1 siRNA transfection. GAPDH 849 loading control. *E*, Representative low and high magnification confocal images of immunostains 850 for CD206 (red), IL-4R α (white) and Fizz1 (green) of hearts from sham and HF hearts (border zone) from MM Oligo- or IL-4R α ASO-treated mice, with quantitation of CD206⁺IL-4R α^* Fizz1⁺ 851 852 and CD206⁺IL-4R α ⁻Fizz1⁻ macrophages, and IL-4R α fluorescent intensity (arbitrary units [a.u.]) n=5-8/group. DAPI (blue) was used to label nuclei. Red arrows indicate CD206⁺IL-4Rα⁻Fizz1⁻ 853 854 cells and yellow arrows indicate CD206⁺IL-4Rα⁺Fizz1⁺ cells. Statistics: 2-way ANOVA followed 855 by Tukey's multiple comparison test, except 1-way ANOVA followed by Tukey's multiple 856 comparison test in panel *C*; **p*<0.05, ***p*<0.01 vs. Ctrl in *C*; ***p*<0.01 vs. Ctrl-scramble siRNA, ## 857 *p*<0.01 vs. rmFIZZ1-scramble siRNA in *D***.** N=6 per group. MM, mismatched; ASO, antisense 858 oligonucleotide.

859 **Figure 8. Alternatively activated cardiac macrophages expand, express IL-4R** α **and** 860 **FIZZ3, and directly correlate with fibrosis in human heart failure (HF).** *A*, Representative 861 flow plots for CD45⁺Autofluorescence(Auto)⁺CD64⁺CD206⁺ macrophages and their CCR2 862 expression, and group quantitation for CD206⁺ macrophages in normal control (Ctrl; n=3) and 863 failing (n=13) human hearts (from LV assist device core tissue). *B*, Representative trichrome 864 stains (*Top*) and low and high magnification (immuno)stains for CD163 (red) and collagen-865 hybridizing peptide (CHP, green) (*Bottom*) of Ctrl and failing human hearts, with corresponding 866 quantitation of cardiac fibrosis (10 Ctrl, 19 failing hearts) and CHP-associated and - 867 unassociated CD163⁺ macrophage frequency (n=7/group). *C*, Low and high magnification 868 confocal images of immunostains for CD163 (white), IL-4R α (red) and Fizz3 (green) in normal 869 (Ctrl; n=4) and failing (n=8) human hearts (HF), and quantitation of IL-4R α^* Fizz3⁺ and IL-870 $-4R\alpha$ ⁻Fizz3⁻ CD163⁺ macrophages. DAPI (blue) was used to label nuclei. White arrows indicate 871 CD163⁺IL-4Rα⁻Fizz3⁻ cells, and yellow arrows indicate CD163⁺IL-4Rα⁺Fizz3⁺ cells. Also shown 872 is the correlation between CD163⁺ macrophage abundance and LV fibrosis in human HF, n=19. 873 Statistics: Mann-Whitney test in *A*; unpaired Student's t test in *B-C;* Pearson R correlation test 874 in *C, lower right panel*.

REFERENCES

- 1. Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. *Nat Rev Cardiol*. 2020;17:269-285. doi: 10.1038/s41569- 019-0315-x
- 2. Bajpai G, Schneider C, Wong N, Bredemeyer A, Hulsmans M, Nahrendorf M, Epelman S, Kreisel D, Liu Y, Itoh A, et al. The human heart contains distinct macrophage subsets with divergent origins and functions. *Nat Med*. 2018;24:1234-1245. doi: 10.1038/s41591- 018-0059-x
- 3. Heidt T, Courties G, Dutta P, Sager HB, Sebas M, Iwamoto Y, Sun Y, Da Silva N, Panizzi P, van der Laan AM, et al. Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction. *Circ Res*. 2014;115:284- 295. doi: 10.1161/CIRCRESAHA.115.303567
- 4. Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD. Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. *Circ Res*. 2014;114:266-282. doi: 10.1161/CIRCRESAHA.113.301720
- 5. Sager HB, Hulsmans M, Lavine KJ, Moreira MB, Heidt T, Courties G, Sun Y, Iwamoto Y, Tricot B, Khan OF, et al. Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure. *Circ Res*. 2016;119:853-864. doi: 10.1161/CIRCRESAHA.116.309001
- 6. Dick SA, Macklin JA, Nejat S, Momen A, Clemente-Casares X, Althagafi MG, Chen J, Kantores C, Hosseinzadeh S, Aronoff L, et al. Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction. *Nat Immunol*. 2019;20:29-39. doi: 10.1038/s41590-018-0272-2
- 7. Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B, Brija T, Gautier EL, Ivanov S, Satpathy AT, et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. *Immunity*. 2014;40:91-104. doi: 10.1016/j.immuni.2013.11.019
- 8. Lavine KJ, Epelman S, Uchida K, Weber KJ, Nichols CG, Schilling JD, Ornitz DM, Randolph GJ, Mann DL. Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. *Proc Natl Acad Sci U S A*. 2014;111:16029-16034. doi: 10.1073/pnas.1406508111
- 9. Bajpai G, Bredemeyer A, Li W, Zaitsev K, Koenig AL, Lokshina I, Mohan J, Ivey B, Hsiao HM, Weinheimer C, et al. Tissue Resident CCR2- and CCR2+ Cardiac Macrophages Differentially Orchestrate Monocyte Recruitment and Fate Specification Following Myocardial Injury. *Circ Res*. 2019;124:263-278. doi: 10.1161/CIRCRESAHA.118.314028
- 10. Hilgendorf I, Gerhardt LM, Tan TC, Winter C, Holderried TA, Chousterman BG, Iwamoto Y, Liao R, Zirlik A, Scherer-Crosbie M, et al. Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium. *Circ Res*. 2014;114:1611-1622. doi: 10.1161/CIRCRESAHA.114.303204
- 11. Prabhu SD, Frangogiannis NG. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. *Circ Res*. 2016;119:91-112. doi: 10.1161/CIRCRESAHA.116.303577
- 12. Prabhu SD. The Cardiosplenic Axis Is Essential for the Pathogenesis of Ischemic Heart Failure. *Trans Am Clin Climatol Assoc*. 2018;129:202-214.
- 13. Revelo XS, Parthiban P, Chen C, Barrow F, Fredrickson G, Wang H, Yucel D, Herman A, van Berlo JH. Cardiac Resident Macrophages Prevent Fibrosis and Stimulate Angiogenesis. *Circ Res*. 2021;129:1086-1101. doi: 10.1161/CIRCRESAHA.121.319737
- 14. Martini E, Kunderfranco P, Peano C, Carullo P, Cremonesi M, Schorn T, Carriero R, Termanini A, Colombo FS, Jachetti E, et al. Single-Cell Sequencing of Mouse Heart

 Immune Infiltrate in Pressure Overload-Driven Heart Failure Reveals Extent of Immune Activation. *Circulation*. 2019;140:2089-2107. doi: 10.1161/CIRCULATIONAHA.119.041694

- 15. Shiraishi M, Shintani Y, Shintani Y, Ishida H, Saba R, Yamaguchi A, Adachi H, Yashiro 929 K, Suzuki K. Alternatively activated macrophages determine repair of the infarcted adult murine heart. *J Clin Invest*. 2016;126:2151-2166. doi: 10.1172/JCI85782
- 16. Yan X, Anzai A, Katsumata Y, Matsuhashi T, Ito K, Endo J, Yamamoto T, Takeshima A, Shinmura K, Shen W, et al. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. *J Mol Cell Cardiol*. 2013;62:24-35. doi: 10.1016/j.yjmcc.2013.04.023
- 17. Leblond AL, Klinkert K, Martin K, Turner EC, Kumar AH, Browne T, Caplice NM. Systemic and Cardiac Depletion of M2 Macrophage through CSF-1R Signaling Inhibition Alters Cardiac Function Post Myocardial Infarction. *PLoS One*. 2015;10:e0137515. doi: 10.1371/journal.pone.0137515
- 18. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. *Immunity*. 2010;32:593-604. doi: 10.1016/j.immuni.2010.05.007
- 19. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000Prime Rep*. 2014;6:13. doi: 10.12703/P6-13
- 20. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity*. 2014;41:14-20. doi: 10.1016/j.immuni.2014.06.008
- 21. Wynn TA, Vannella KM. Macrophages in Tissue Repair, Regeneration, and Fibrosis. *Immunity*. 2016;44:450-462. doi: 10.1016/j.immuni.2016.02.015
- 22. Tugal D, Liao X, Jain MK. Transcriptional control of macrophage polarization. *Arterioscler Thromb Vasc Biol*. 2013;33:1135-1144. doi: 10.1161/ATVBAHA.113.301453
- 23. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. *Trends Immunol*. 2004;25:677-686. doi: 10.1016/j.it.2004.09.015
- 24. Shintani Y, Ito T, Fields L, Shiraishi M, Ichihara Y, Sato N, Podaru M, Kainuma S, Tanaka H, Suzuki K. IL-4 as a Repurposed Biological Drug for Myocardial Infarction through Augmentation of Reparative Cardiac Macrophages: Proof-of-Concept Data in Mice. *Sci Rep*. 2017;7:6877. doi: 10.1038/s41598-017-07328-z
- 25. Tang PM, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis. *Nat Rev Nephrol*. 2019;15:144-158. doi: 10.1038/s41581-019- 0110-2
- 26. Bansal SS, Ismahil MA, Goel M, Patel B, Hamid T, Rokosh G, Prabhu SD. Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure. *Circ Heart Fail*. 2017;10:e003688. doi: 10.1161/CIRCHEARTFAILURE.116.003688
- 27. Herbert DR, Holscher C, Mohrs M, Arendse B, Schwegmann A, Radwanska M, Leeto M, Kirsch R, Hall P, Mossmann H, et al. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. *Immunity*. 2004;20:623-635. doi: 10.1016/s1074-7613(04)00107-4
- 28. Vishlaghi N, Guo L, Griswold-Wheeler D, Sun Y, Booker C, Crossley JL, Bancroft AC, Juan C, Korlakunta S, Ramesh S, et al. Vegfc-expressing cells form heterotopic bone after musculoskeletal injury. *Cell Rep*. 2024;43:114049. doi: 10.1016/j.celrep.2024.114049
- 29. Bansal SS, Ismahil MA, Goel M, Zhou G, Rokosh G, Hamid T, Prabhu SD. Dysfunctional and Proinflammatory Regulatory T-Lymphocytes Are Essential for Adverse Cardiac Remodeling in Ischemic Cardiomyopathy. *Circulation*. 2019;139:206-221. doi: 975 10.1161/CIRCULATIONAHA.118.036065
- 30. Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, Prabhu SD. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. *Circulation*. 2009;119:1386-1397. doi: 10.1161/CIRCULATIONAHA.108.802918
- 31. Wang G, Hamid T, Keith RJ, Zhou G, Partridge CR, Xiang X, Kingery JR, Lewis RK, Li Q, Rokosh DG, et al. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. *Circulation*. 2010;121:1912-1925. doi: 10.1161/CIRCULATIONAHA.109.905471
- 32. Patel B, Bansal SS, Ismahil MA, Hamid T, Rokosh G, Mack M, Prabhu SD. CCR2(+) Monocyte-Derived Infiltrating Macrophages Are Required for Adverse Cardiac Remodeling During Pressure Overload. *JACC Basic Transl Sci*. 2018;3:230-244. doi: 10.1016/j.jacbts.2017.12.006
- 33. Hamid T, Xu Y, Ismahil MA, Rokosh G, Jinno M, Zhou G, Wang Q, Prabhu SD. Cardiac Mesenchymal Stem Cells Promote Fibrosis and Remodeling in Heart Failure: Role of PDGF Signaling. *JACC Basic Transl Sci*. 2022;7:465-483. doi: 10.1016/j.jacbts.2022.01.004
- 34. Wang Q, Wang S, Sun Z. Kidney-Specific Klotho Gene Deletion Causes Aortic Aneurysm via Hyperphosphatemia. *Hypertension*. 2021;78:308-319. doi: 10.1161/HYPERTENSIONAHA.121.17299
- 35. Tang L, Zhang H, Wang C, Li H, Zhang Q, Bai J. M2A and M2C Macrophage Subsets Ameliorate Inflammation and Fibroproliferation in Acute Lung Injury Through Interleukin 10 Pathway. *Shock*. 2017;48:119-129. doi: 10.1097/SHK.0000000000000820
- 36. Hamid T, Xu Y, Ismahil MA, Li Q, Jones SP, Bhatnagar A, Bolli R, Prabhu SD. TNF receptor signaling inhibits cardiomyogenic differentiation of cardiac stem cells and promotes a neuroadrenergic-like fate. *Am J Physiol Heart Circ Physiol*. 2016;311:H1189- H1201. doi: 10.1152/ajpheart.00904.2015
- 37. Bujak M, Ratkaj I, Markova-Car E, Jurisic D, Horvatic A, Vucinic S, Lerga J, Baus-Loncar M, Pavelic K, Kraljevic Pavelic S. Inflammatory Gene Expression Upon TGF-beta1- Induced p38 Activation in Primary Dupuytren's Disease Fibroblasts. *Front Mol Biosci*. 2015;2:68. doi: 10.3389/fmolb.2015.00068
- 38. Covarrubias R, Ismahil MA, Rokosh G, Hamid T, Accornero F, Singh H, Gumina RJ, Prabhu SD, Bansal SS. Optimized protocols for isolation, fixation, and flow cytometric characterization of leukocytes in ischemic hearts. *Am J Physiol Heart Circ Physiol*. 2019;317:H658-H666. doi: 10.1152/ajpheart.00137.2019
- 39. Trouplin V, Boucherit N, Gorvel L, Conti F, Mottola G, Ghigo E. Bone marrow-derived macrophage production. *J Vis Exp*. 2013:e50966. doi: 10.3791/50966
- 40. Ripple MJ, You D, Honnegowda S, Giaimo JD, Sewell AB, Becnel DM, Cormier SA. Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease. *J Immunol*. 2010;185:4804-4811. doi: 10.4049/jimmunol.1000484
- 41. Weng SY, Wang X, Vijayan S, Tang Y, Kim YO, Padberg K, Regen T, Molokanova O, Chen T, Bopp T, et al. IL-4 Receptor Alpha Signaling through Macrophages Differentially Regulates Liver Fibrosis Progression and Reversal. *EBioMedicine*. 2018;29:92-103. doi: 10.1016/j.ebiom.2018.01.028
- 42. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. *J Exp Med*. 2007;204:3037-3047. doi: 10.1084/jem.20070885
- 43. Bakhshian Nik A, Alvarez-Argote S, O'Meara CC. Interleukin 4/13 signaling in cardiac regeneration and repair. *Am J Physiol Heart Circ Physiol*. 2022;323:H833-H844. doi: 10.1152/ajpheart.00310.2022

- 44. Shankar A, McAlees JW, Lewkowich IP. Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease. *J Allergy Clin Immunol*. 2022;150:266-276. doi: 10.1016/j.jaci.2022.06.012
- 45. Junttila IS. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes. *Front Immunol*. 2018;9:888. doi: 10.3389/fimmu.2018.00888
- 46. Krawiec P, Pawlowska-Kamieniak A, Pac-Kozuchowska E. Interleukin 10 and interleukin 10 receptor in paediatric inflammatory bowel disease: from bench to bedside lesson. *J Inflamm (Lond)*. 2021;18:13. doi: 10.1186/s12950-021-00279-3
- 47. Walter MR. The molecular basis of IL-10 function: from receptor structure to the onset of signaling. *Curr Top Microbiol Immunol*. 2014;380:191-212. doi: 10.1007/978-3-662- 1037 43492-5 9
- 48. Jones B, Debski A, Hans CP, Go MR, Agarwal G. Structurally abnormal collagen fibrils in abdominal aortic aneurysm resist platelet adhesion. *J Thromb Haemost*. 2022;20:470- 477. doi: 10.1111/jth.15576
- 49. Cao Q, Wang Y, Zheng D, Sun Y, Wang Y, Lee VW, Zheng G, Tan TK, Ince J, Alexander SI, et al. IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. *J Am Soc Nephrol*. 2010;21:933-942. doi: 10.1681/ASN.2009060592
- 50. Roszer T. Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms. *Mediators Inflamm*. 2015;2015:816460. doi: 10.1155/2015/816460
- 51. Nair MG, Du Y, Perrigoue JG, Zaph C, Taylor JJ, Goldschmidt M, Swain GP, Yancopoulos GD, Valenzuela DM, Murphy A, et al. Alternatively activated macrophage- derived RELM-{alpha} is a negative regulator of type 2 inflammation in the lung. *J Exp Med*. 2009;206:937-952. doi: 10.1084/jem.20082048
- 52. Nair MG, Gallagher IJ, Taylor MD, Loke P, Coulson PS, Wilson RA, Maizels RM, Allen JE. Chitinase and Fizz family members are a generalized feature of nematode infection with selective upregulation of Ym1 and Fizz1 by antigen-presenting cells. *Infect Immun*. 2005;73:385-394. doi: 10.1128/IAI.73.1.385-394.2005
- 53. Liu T, Hu B, Choi YY, Chung M, Ullenbruch M, Yu H, Lowe JB, Phan SH. Notch1 signaling in FIZZ1 induction of myofibroblast differentiation. *Am J Pathol*. 2009;174:1745-1755. doi: 10.2353/ajpath.2009.080618
- 54. Liu T, Yu H, Ullenbruch M, Jin H, Ito T, Wu Z, Liu J, Phan SH. The in vivo fibrotic role of FIZZ1 in pulmonary fibrosis. *PLoS One*. 2014;9:e88362. doi: 10.1371/journal.pone.0088362
- 55. Jenkins SJ, Ruckerl D, Thomas GD, Hewitson JP, Duncan S, Brombacher F, Maizels RM, Hume DA, Allen JE. IL-4 directly signals tissue-resident macrophages to proliferate beyond homeostatic levels controlled by CSF-1. *J Exp Med*. 2013;210:2477-2491. doi: 10.1084/jem.20121999
- 56. Rizzo P, Miele L, Ferrari R. The Notch pathway: a crossroad between the life and death of the endothelium. *Eur Heart J*. 2013;34:2504-2509. doi: 10.1093/eurheartj/ehs141
- 57. Talele NP, Fradette J, Davies JE, Kapus A, Hinz B. Expression of alpha-Smooth Muscle Actin Determines the Fate of Mesenchymal Stromal Cells. *Stem Cell Reports*. 2015;4:1016-1030. doi: 10.1016/j.stemcr.2015.05.004
- 58. Lurier EB, Dalton D, Dampier W, Raman P, Nassiri S, Ferraro NM, Rajagopalan R, Sarmady M, Spiller KL. Transcriptome analysis of IL-10-stimulated (M2c) macrophages by next-generation sequencing. *Immunobiology*. 2017;222:847-856. doi: 10.1016/j.imbio.2017.02.006
- 59. Pine GM, Batugedara HM, Nair MG. Here, there and everywhere: Resistin-like molecules in infection, inflammation, and metabolic disorders. *Cytokine*. 2018;110:442- 451. doi: 10.1016/j.cyto.2018.05.014

- 60. Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and therapeutic aspects. *Antioxid Redox Signal*. 2013;18:2352-2363. doi: 10.1089/ars.2012.4834
- 61. Frangogiannis NG. Cardiac fibrosis. *Cardiovasc Res*. 2021;117:1450-1488. doi: 10.1093/cvr/cvaa324
- 62. Pechkovsky DV, Prasse A, Kollert F, Engel KM, Dentler J, Luttmann W, Friedrich K, Muller-Quernheim J, Zissel G. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. *Clin Immunol*. 2010;137:89-101. doi: 10.1016/j.clim.2010.06.017
- 63. Wang J, Xu L, Xiang Z, Ren Y, Zheng X, Zhao Q, Zhou Q, Zhou Y, Xu L, Wang Y. Microcystin-LR ameliorates pulmonary fibrosis via modulating CD206(+) M2-like macrophage polarization. *Cell Death Dis*. 2020;11:136. doi: 10.1038/s41419-020-2329-z
- 64. Carlson S, Helterline D, Asbe L, Dupras S, Minami E, Farris S, Stempien-Otero A. Cardiac macrophages adopt profibrotic/M2 phenotype in infarcted hearts: Role of urokinase plasminogen activator. *J Mol Cell Cardiol*. 2017;108:42-49. doi: 10.1016/j.yjmcc.2016.05.016
- 65. Sieweke MH, Allen JE. Beyond stem cells: self-renewal of differentiated macrophages. *Science*. 2013;342:1242974. doi: 10.1126/science.1242974
- 66. Martinez FO, Helming L, Milde R, Varin A, Melgert BN, Draijer C, Thomas B, Fabbri M, Crawshaw A, Ho LP, et al. Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. *Blood*. 2013;121:e57-69. doi: 10.1182/blood-2012-06-436212
- 67. Kim JE, Jung K, Kim JA, Kim SH, Park HS, Kim YS. Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity. *Sci Rep*. 2019;9:7772. doi: 10.1038/s41598-019-44253-9
- 68. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. *EMBO J*. 2000;19:4046-4055. doi: 10.1093/emboj/19.15.4046
- 69. Chemaly ER, Hadri L, Zhang S, Kim M, Kohlbrenner E, Sheng J, Liang L, Chen J, P KR, Hajjar RJ, et al. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. *J Mol Cell Cardiol*. 2011;51:144-155. doi: 10.1016/j.yjmcc.2011.04.006
- 70. Takeishi Y, Niizeki T, Arimoto T, Nozaki N, Hirono O, Nitobe J, Watanabe T, Takabatake N, Kubota I. Serum resistin is associated with high risk in patients with congestive heart failure--a novel link between metabolic signals and heart failure. *Circ J*. 2007;71:460-464. doi: 10.1253/circj.71.460
-

